

1
2
3
4
5
6
7
8
9
10
11

**ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs)
FOR
ACRYLONITRILE
(CAS Reg. No. 107-13-1)**

12
13
14
15
16
17
18
19
20
21
22



1
2
3
4
5
6
7
8
9
10

**ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs)
FOR
ACRYLONITRILEE
(CAS Reg. No. 107-13-1)**

PREFACE

1
2
3 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of
4 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous
5 Substances (NAC/AEGL Committee) has been established to identify, review and interpret
6 relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic
7 chemicals.
8

9 AEGLs represent threshold exposure limits for the general public and are applicable to
10 emergency exposure periods ranging from 10 minutes to 8 hours. Three levels - AEGL-1,
11 AEGL-2 and AEGL-3 — are developed for each of five exposure periods (10 and 30 minutes, 1
12 hour, 4 hours, and 8 hours) and are distinguished by varying degrees of severity of toxic effects.
13 The three AEGLs are defined as follows:
14

15 AEGL-1 is the airborne concentration (expressed as parts per million or milligrams per
16 cubic meter [ppm or mg/m³]) of a substance above which it is predicted that the general
17 population, including susceptible individuals, could experience notable discomfort, irritation, or
18 certain asymptomatic, non-sensory effects. However, the effects are not disabling and are
19 transient and reversible upon cessation of exposure.
20

21 AEGL-2 is the airborne concentration (expressed as ppm or mg/m³) of a substance above
22 which it is predicted that the general population, including susceptible individuals, could
23 experience irreversible or other serious, long-lasting adverse health effects or an impaired ability
24 to escape.
25

26 AEGL-3 is the airborne concentration (expressed as ppm or mg/m³) of a substance above
27 which it is predicted that the general population, including susceptible individuals, could
28 experience life-threatening health effects or death.
29

30 Airborne concentrations below the AEGL-1 represent exposure levels that could produce
31 mild and progressively increasing but transient and nondisabling odor, taste, and sensory
32 irritation or certain asymptomatic, non-sensory effects. With increasing airborne concentrations
33 above each AEGL, there is a progressive increase in the likelihood of occurrence and the
34 severity of effects described for each corresponding AEGL. Although the AEGL values
35 represent threshold levels for the general public, including susceptible subpopulations, such as
36 infants, children, the elderly, persons with asthma, and those with other illnesses, it is recognized
37 that individuals, subject to unique or idiosyncratic responses, could experience the effects
38 described at concentrations below the corresponding AEGL.
39
40

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

TABLE OF CONTENTS

PREFACE.....	2
LIST OF TABLES.....	5
EXECUTIVE SUMMARY	6
1. INTRODUCTION.....	9
2. HUMAN TOXICITY DATA.....	9
2.1. Acute Lethality	9
2.2. Nonlethal Toxicity	9
2.3. Developmental/Reproductive Effects	11
2.4. Genotoxicity	11
2.4.1. In Vitro Studies	11
2.4.2. In Vivo Studies	12
2.5. Carcinogenicity.....	13
2.6. Summary.....	14
3. ANIMAL TOXICITY DATA.....	14
3.1. Acute Lethality	14
3.1.1. Monkey	14
3.1.2. Rat.....	14
3.1.3. Dog	17
3.1.4. Guinea pig.....	17
3.1.5. Cat.....	18
3.1.6. Rabbit.....	18
3.2. Nonlethal Toxicity	18
3.2.1. Monkey	18
3.2.2. Dog	19
3.2.3. Cat.....	19
3.2.4. Rat.....	19
3.2.5. Rabbit.....	20
3.2.6. Guinea pig.....	20
3.3. Developmental/Reproductive Effects	20
3.4. Genotoxicity	22
3.5. Carcinogenicity.....	23
3.6. Summary.....	24
4. SPECIAL CONSIDERATIONS	25
4.1. Metabolism and Disposition	25
4.2. Mechanism of Toxicity.....	26
4.3. Structure-Activity Relationships.....	27
4.4. Species Variability.....	27
4.5. Susceptible populations	27
4.6. Concurrent Exposure Issues	28
5. DATA ANALYSIS FOR AEGL-1	28
5.1. Human Data Relevant to AEGL-1	28
5.2. Animal Data Relevant to AEGL-1.....	28
5.3. Derivation of AEGL-1 Values	29
6. DATA ANALYSIS FOR AEGL-2	29
6.1. Human Data Relevant to AEGL-2.....	29
6.2. Animal Data Relevant to AEGL-2.....	29

1 6.3. Derivation of AEGL-2 Values30

2 7. DATA ANALYSIS FOR AEGL-330

3 7.1. Human Data Relevant to AEGL-330

4 7.2. Animal Data Relevant to AEGL-330

5 7.3. Derivation of AEGL-3 Values31

6 8. SUMMARY OF AEGLs31

7 8.1. AEGL Values and Toxicity Endpoints31

8 8.2. Comparisons with Other Standards and Guidelines32

9 8.3. Data Adequacy and Research Needs34

10 9. REFERENCES34

11 APPENDIX A: DERIVATION OF AEGL VALUES41

12 APPENDIX B: TIME SCALING CALCULATIONS47

13 APPENDIX C: AEGL DERIVATION SUMMARY TABLES49

14 APPENDIX D: BMC ANALYSIS FOR ACRYLONITRILE53

15 APPENDIX E: LITCHFIELD AND WILCOXON LC₅₀ CALCULATION65

16 APPENDIX F: CARCINOGENICITY ASSESSMENT FOR ACRYLONITRILE68

17 APPENDIX G: CATEGORY PLOT FOR ACRYLONITRILE70

18

LIST OF TABLES

1
2
3 **S 1. SUMMARY OF AEGL VALUES FOR ACRYLONITRILE (AN)** 8
4 TABLE 1. CHEMICAL AND PHYSICAL DATA FOR ACRYLONITRILE (AN)..... 9
5 TABLE 2. TOXICITY OF AN VAPOR IN RATS EXPOSED FOR 0.5 TO 8 HOURS..... 15
6 TABLE 3. TOXICITY OF AN VAPOR IN RATS EXPOSED FOR 4 HOURS..... 15
7 TABLE 4. LETHAL RESPONSE OF RATS EXPOSED TO AN AT VARIOUS EXPOSURE
8 CONCENTRATION/DURATIONS 16
9 TABLE 5. LETHALITY IN RATS FOLLOWING NOSE-ONLY INHALATION EXPOSURE TO AN FOR 4
10 HOURS 16
11 TABLE 6. TOXICITY OF AN VAPOR IN DOGS EXPOSED FOR 4 HOURS. 17
12 TABLE 7. TOXICITY OF AN VAPOR IN GUINEA PIGS EXPOSED FOR 4 HOURS 18
13 TABLE 8. MATERNAL TOXICITY AMONG RATS EXPOSED BY INHALATION TO ACRYLONITRILE
14 (AN) 21
15 TABLE 9. LITTER DATA FOR PREGNANT RATS EXPOSED TO ACRYLONITRILE (AN) VAPOR 21
16 TABLE 10. INCIDENCE OF FETAL MALFORMATIONS AMONG LITTERS OF RATS EXPOSED TO
17 ACRYLONITRILE (AN) VAPOR 21
18 TABLE 11. REPRODUCTIVE PARAMETERS IN RATS EXPOSED TO ACRYLONITRILE (AN) VAPOR ON
19 GESTATION DAYS 6-20..... 22
20 TABLE 12. TUMOR TYPE AND INCIDENCE DATA FOR RATS EXPOSED TO ACRYLONITRILE (AN)
21 VAPOR 24
22 TABLE 13. AEGL-1 VALUES FOR ACRYLONITRILE 29
23 TABLE 14. AEGL-2 VALUES FOR ACRYLONITRIL 30
24 TABLE 15. AEGL-3 VALUES FOR ACRYLONITRILE 31
25 TABLE 16. AEGL VALUES FOR ACRYLONITRILE 32
26 TABLE 17. EXTANT STANDARDS AND GUIDELINES FOR ACRYLONITRILE..... 32
27

EXECUTIVE SUMMARY

Acrylonitrile (CAS Reg. No. 107-13-1) is a monomer used in the manufacture of acrylic fibers, synthetic rubber, resins, plastics, adhesives, and acrylamide. Acrylonitrile (AN) has a sharp onion-garlic odor. World-wide production is estimated at 4 to 4.5 million metric tons. A concentration range of 1.6 - 36.3 ppm has been reported as AN odor thresholds for humans.

Nonlethal effects of occupational exposure to AN include headache, nasal and ocular irritation, thoracic discomfort, nervousness and irritability. Available information indicates that these effects occur at 12-15 ppm regardless of exposure duration and resolve following removal from exposure. No signs or symptoms were reported for informed male volunteer subjects following exposure up to 4.6 ppm for 8 hours (Jakubowski et al., 1987). Lethality following acute inhalation exposure to AN has been reported but no exposure terms are available. Limited information suggest that children may be more susceptible to the effects of acute inhalation exposure than adults.

Acute exposure data are available for several laboratory species (monkey, rat, dog, rabbit, guinea pig, cat) and demonstrate qualitatively similar responses ranging from mild irritation (redness of exposed skin, lacrimation, nasal discharge) and mild effects on ventilation and cardiovascular responses to severe respiratory effects, convulsions, and death. Four-hour exposure to concentrations ranging from 30 to 100 ppm produced little or no effect in most species tested but dogs appeared to be notably more sensitive exhibiting severe effects at the 100-ppm exposure level. Results of a recent nose-only exposure study in rats showed that concentrations up to 50 ppm for 6 hours or 225 ppm for 1.75 hours produced only minor transient effects on blood pressure. Lethality in rats appears to occur at cumulative exposure of 1800-1900 ppm-hrs for 0.5 to 6-hour exposure durations, although for nose-only exposures this is notably higher (- 3800 ppm-hrs). Analysis of exposure concentration-duration data suggest a near linear relationship (i.e., $n = 1.1$ for $C^n \times t = k$). Results of studies in animals showed that lethality may be delayed especially at the lower limits of lethal exposures. One study provided evidence for teratogenic effects in rats following gestational exposure of dams to 80 ppm but not at 40 ppm AN. Another study showed an exposure-related decrease in fetal weight following gestational exposure of dams to 25, 50, or 100 ppm AN; no other reproductive/developmental effects were detected. Results of *in vitro* testing suggest that AN is weakly mutagenic. Results of *in vivo* mammalian cell assays measuring various endpoints were generally negative. Results of long-term inhalation exposure cancer bioassays have shown that AN is carcinogenic in rats. The brain, spinal cord, Zymbal's gland, tongue, nonglandular stomach, small intestine, and mammary gland have all been identified as targets.

AN toxicity appears to be directly related to its metabolism. Two major metabolism pathways have been described; conjugation with glutathione and epoxidation by microsomal cytochrome P4502E1 which forms 2-cyanoethylene oxide (CEO). Metabolites from both pathways are subject to additional biotransformation. The glutathione conjugate may form a mercapturic acid which is excreted in urine. CEO is further metabolized via conjugation with glutathione (catalysis with cytosolic GST or nonenzymatically) resulting in additional conjugates and via hydrolysis by microsomal epoxide hydrolase (EH). The secondary metabolites of CEO may also be further metabolized. Cyanide may be generated via the EH pathway and by one of the GSH conjugation products. Cyanide, in turn, is detoxified to thiocyanate via rhodanese-mediated reactions with thiosulfate.

1 Generally, the toxic effects following acute inhalation exposure to AN appear to be
2 irritation of the respiratory tract and the metabolism of AN to cyanide. Acrylonitrile-induced
3 neurological effects in laboratory animals appear to involve the parent compound and the
4 cyanide metabolite. The pivotal role of cyanide has been clearly demonstrated. AN-induced
5 convulsions, are likely the result of cyanide resulting from AN metabolism although recent work
6 suggests that only the early seizures are cyanide-mediated and that severe clonic convulsions
7 preceding death may be due to parent compound.
8

9 The AEGL-1 values were based on the absence of effects in informed human volunteer
10 subjects (6 males) exposed for 8 hours to 4.6 ppm AN (Jakubowski et al., 1987). Industry
11 reports noted that exposure to 12-15 ppm caused ocular irritation and headaches regardless of
12 exposure duration. A 3-fold reduction (an appropriate adjustment for mild irritation effects) of
13 the lower limit of this range is equivalent to the 4.6 ppm no-effect concentration reported by
14 Jakubowski et al. (1987). Therefore, the 4.6 ppm value is recommended for all AEGL-1
15 exposure durations. In light of results of studies showing only mild effects (headache,
16 nervousness, fatigue, nausea, and insomnia) following subchronic occupational exposure to AN
17 levels possibly as high as 20 ppm, further reduction of the AEGL-1 values is not warranted.
18

19 The AEGL-2 values were based upon slight transient effects in rats exposed to 305 ppm
20 AN for 2 hours (Dudley and Neal, 1942). The effects resolved within 12 hours post exposure.
21 Analysis of occupational exposure effects indicated that routine exposure to 10-20 ppm (up to 2-
22 higher than the 8-hr AEGL-2) resulted in complaints of headache, fatigue, nausea, and insomnia
23 which were neither irreversible nor escape-impairing effects. Therefore, the critical effect upon
24 which the AEGL-2 values are based is appropriate. The interspecies uncertainty factor was
25 limited to 3 because PB-PK modeling has shown that predicted concentrations of AN and the
26 metabolite CEO in blood and brain were similar in rats and humans exposed by inhalation. The
27 intraspecies uncertainty factor was limited to 3 because the effects associated with acute
28 irritation effects of AN are not likely to vary greatly among individuals and because metabolism
29 may play only a limited role in the critical effects used as the basis for AEGL-2 derivation. Time
30 scaling for developing AEGL-2 values from the 2-hour experimental POD to AEGL-specific
31 exposure durations was performed using $C^n \times t = k$, where $n = 1.1$.
32

33 The AEGL-3 values were derived using 30-minute, 1-, 4-, and 8-hour BMCL₀₅ estimates
34 of lethality threshold. Data for several AEGL-specific exposure periods were available from the
35 reports by Apple et al. (1981) and Dudley and Neal (1942). A 30-minute BMCL₀₅ of 1748 ppm
36 was calculated from the Appel et al. (1981a) data. The 1-hr, 2-hr, 4-hr, and 8-hr BMCL₀₅ values
37 derived from lethality data published by Dudley and Neal (1942) are 1024.4, 491.3, 179.5 and
38 185.8 ppm, respectively, for rats exposed to various concentrations of AN for 1, 2, 4, or 8 hours.
39 With the exception of the 4-hour value, the resulting BMCL₀₅ values are relationally consistent
40 across time and the 30-minute, 1-hour, and 8-hour estimates were used to derive corresponding
41 AEGL-3 values. Because the 4-hr value was not used due to the relational inconsistency, the 4-
42 hour AEGL-3 value was derived by time-scaling the 8-hour BMCL₀₅ of 185.9 ppm. Although
43 the dog appeared to be the most sensitive species, the overall database for rats is more robust
44 thereby justifying use of the rat data. Further justification for limiting the interspecies
45 uncertainty factor to 3 comes from PBPK models demonstrating that predicted concentrations of
46 AN and the metabolite CEO in blood and brain were similar in rats and humans exposed by
47 inhalation. The PBPK model for AN and CEO disposition in humans utilized human *in vitro*
48 data and scaling from a rat model (Kedderis and Fennell, 1996) that incorporated major
49 biotransformation and reactivity pathways. These included metabolism of AN to glutathione

1 conjugates and CEO, reaction rates of AN and CEO with glutathione and tissue components, and
 2 the metabolism of CEO by hydrolysis and glutathione conjugation. For effects resulting from a
 3 single acute exposure, an intraspecies uncertainty factor of 3 may be considered sufficient for
 4 accounting for variability in metabolism-mediated effects. Additional uncertainty factor
 5 application would result in incompatibility between AEGL-3 and AEGL-2 values.
 6

7 Various inhalation unit risk values have been developed for acrylonitrile. IARC
 8 downgraded AN from category 2a to category 2b noting that data relative to human
 9 carcinogenicity are inadequate and that no causal association exists. Current data are sufficient
 10 for considering AN to be carcinogenic in animals following long-term inhalation exposure. That
 11 AN would induce a carcinogenic response in humans following a single, once-in-a-lifetime acute
 12 exposure is remote.
 13

14 The AEGL values for acrylonitrile are summarized in the following table.
 15

S 1. Summary of AEGL Values for Acrylonitrile (AN)						
Classification	10-min	30-min	1-h	4-h	8-h	Endpoint (Reference)
AEGL-1 (Nondisabling)	4.6 ppm (10 mg/m ³)	4.6 ppm (10 mg/m ³)	4.6 ppm (10 mg/m ³)	4.6 ppm (10 mg/m ³)	4.6 ppm (10 mg/m ³)	No effect in volunteer human subjects exposed to 4.6 ppm for 8 hrs; UF=1x1 (Jakubowski et al., 1987)
AEGL-2 (Disabling)	290 ppm (630 mg/m ³)	110 ppm (240 mg/m ³)	57 ppm (120 mg/m ³)	16 ppm (35 mg/m ³)	8.6 ppm (19 mg/m ³)	Slight transient effects in rats exposed for 2 hrs to 3-5 ppm; UF=3x3; n=1.1 (Dudley and Neal, 1942)
AEGL-3 (Lethality)	480 ppm (1000 mg/m ³)	180 ppm (390 mg/m ³)	100 ppm (217 mg/m ³)	35 ppm (76 mg/m ³)	19 ppm (41 mg/m ³)	30-min, 1-hr, and 8-hr, BMCL ₀₅ lethality threshold estimates in rats; UF=3x3; n=1.1 (Appel et al., 1981a; Dudley and Neal, 1942)

16 17 18 References

- 19
 20 Appel, K.E., Peter, H., and Bolt, H.M. 1981a. Effect of potential antidotes on the acute toxicity of
 21 acrylonitrile. *Int. Arch. Occup. Environ. Health*, 49: 157-163.
 22
 23 Dudley, H.C. and Neal, P.A. 1942. Toxicology of acrylonitrile (vinyl cyanide). I. Study of the acute
 24 toxicity. *J. Ind. Hyg. Toxicol.*, 24 (2): 27-36.
 25
 26 Jakubowski, M., Linhart, I., Pielas, G., Kopecky, J. 1987. 2-Cyanoethylmercapturic acid (CEMA) in the
 27 urine as a possible indicator of exposure to acrylonitrile. *Brit. J. Industr. Med.* 44: 843-840.

1. INTRODUCTION

Acrylonitrile (CAS Reg. No. 107-13-1) is a monomer used in the manufacture of acrylic fibers, synthetic rubber, resins, plastics, adhesives, and acrylamide. Acrylonitrile (AN) has a sharp onion-garlic odor. Recent world-wide production has been estimated at 4 to 4.5 million metric tons (Collins et al., 2003; NPI, 2007). Production of acrylonitrile in the United States was 3.4 million pounds in 1996 (NTP, 2006).

TABLE 1. Chemical and Physical Data for Acrylonitrile (AN)		
Parameter	Value	Reference
Synonyms	2-propenenitrile; vinyl cyanide; acrylonitrile monomer, cyanoethylene	O'Neil et al., 2001
Chemical formula	C ₃ H ₃ N	O'Neil et al., 2001
Molecular weight	53.06	O'Neil et al., 2001
CAS Registry No.	107-13-1	O'Neil et al., 2001
Physical state	Liquid	O'Neil et al., 2001
Solubility in water	73 g/L at 20 °C	American Cyanamid, 1959
Vapor pressure	100 torr @ 23EC 116 hPa	ACGIH, 1991 BASF AG, 1994
Specific gravity	0.8 @ 23EC	O'Neil et al., 2001
Melting point/boiling point	-83.55 EC @ 0EC/ 77.3EC @ 760 mm	O'Neil et al., 2001
Conversion factors in air	1 ppm = 2.17 mg/m ³ 1 mg/m ³ = 0.46 ppm	

2. HUMAN TOXICITY DATA

2.1. Acute Lethality

A child exposed overnight in a room fumigated with AN died. Vomiting, lacrimation, convulsions, respiratory difficulty, cyanosis, and tachycardia were present. Five adults also in the room experienced little or no effect (see Section 2.2.) (Grunske, 1949). No exposure concentration-duration information was reported.

Loss of consciousness, convulsions, and respiratory arrest have been reported as outcomes of severe acute inhalation exposure to AN (Buchter and Peter, 1984). However, no exposure terms were available.

The death of a worker cleaning an AN-containing wagon at a train depot was attributed to exposure to the chemical (Bader and Wrbitzky, 2006). No exposure terms were available although liquid AN was present on the clothing of the individual. Cause of death was reportedly "blood circulation collapse".

2.2. Nonlethal Toxicity

The AIHA (1989) lists an odor threshold range of 1.6-22 ppm for AN while Ruth (1986) reported a range of 3.7-36.3 ppm.

Wilson et al. (1948) reported that exposure of workers handling "polymerizers" at concentrations of 16-100 ppm for 20-45 minutes experienced dull headaches, nasal and ocular irritation, discomfort in the chest, nervousness and irritability. Workers with notable poisoning

1 experienced nausea, vomiting, and weakness. Some developed mild jaundice, low-grade
2 anemia, and leukocytosis. No exposure terms were provide for the workers with these more
3 serious effects but all recovered upon removal from exposure. Additional reports (NAC/AEGL,
4 pers. communication) affirmed that occupational exposure to 12-15 ppm resulted in ocular
5 irritation and headache.

6
7 Five adults who spent the night in the room in which a child died of AN poisoning (see
8 Section 2.1.), had no signs of poisoning or complained only of eye irritation (Grunske, 1949).
9 No exposure concentration-duration information was reported.

10
11 Subchronic (- 3 years) occupational exposure AN at concentrations ranging from
12 0.6 to 6.0 mg/m³ (- 0.3 to 3 ppm) produced headaches, insomnia, general weakness, decreased
13 working capacity, and irritability (Babanov et al., 1959).

14
15 Lacrimation and visual disturbance were reported for some non-fatal exposures to AN
16 (Davis et al., 1973). Although exposure concentrations were not reported, these effects were
17 likely associated with very high AN concentrations.

18
19 In a report by Sakurai and Kusumoto (1972), the health records of 576 workers working
20 in five AN fiber plants over a 10 year period were examined. Workers exposed to AN
21 concentrations of 11 mg/m³ (5 ppm) complained of headache, fatigue, nausea, and insomnia.
22 There was a positive correlation with exposure time but not with the exposure concentration or
23 age of workers. The report analyzed 4439 examinations acquired over 10 years prior to 1970.
24 Two cohorts, one exposed to concentrations of AN of below 11 mg/m³ (5 ppm) and the other
25 exposed to less than 45 mg/m³ (20 ppm) were considered. In a later report, however, Sakurai et
26 al. (1978) stated that the study lacked adequate epidemiological design, the findings were based
27 on routine health examinations, and the "exposure levels were not reliably reported" and may
28 have been much higher. In this later appraisal it was noted that many of the symptoms were
29 associated with exposures well in excess of 5 ppm. Sakurai et al. (1978) stated that their
30 findings were not contradictory to those of Wilson et al. (1948) reflecting the older and less
31 controlled workplace environment where levels could be up to 20 ppm.

32
33 Ocular irritation was a primary effect in a 24-year old man whose face, eyes and body
34 were sprayed by AN (no exposure concentration data) explosively released from a defective
35 valve (Vogel and Kirkendall, 1984). Mild conjunctivitis with no corneal clouding was reported.
36 Results of fundascopic examination were normal.

37
38 A study was conducted to evaluate the metabolism and excretion of AN in human
39 informed volunteer subjects (Jakubowski et al., 1987). The six volunteers (including the
40 investigators) were all males aged 28-45. Being toxicologists, they were all aware of the toxic
41 properties of AN. The subjects were exposed for 8 hours to AN vapors generated by a saturator
42 immersed in a thermostat-controlled water bath and diluted with carrier air to produce the
43 desired AN concentrations (5 or 10 mg/m³; equivalent to 2.3 and 4.6 ppm, respectively).
44 Airflow in the 11.7 m³ chamber was approximately 200 m³/hr. There were three 10-minute
45 breaks from the exposure at 2, 4, and 6 hours. Gas chromatography was used to monitor the AN
46 concentration every 15 minutes. No symptoms were reported by any of the subjects.

47
48 The World Health Organization (WHO, 1983) summarized various workplace studies
49 (Zotova, 1975; Delivanova et al., 1978; Enikeeva et al., 1976; Ivanov, 1983).

1 Blepharoconjunctivitis was reported following exposure to 5 ppm AN. Other non-ocular
2 symptoms were also reported.

3
4 Ginceva et al. (1977) reported no changes in the health status for a group of 23 men
5 occupationally exposed to 1.9 to 3.3 ppm AN for three to five years.

6 7 **2.3. Developmental/Reproductive Effects**

8
9 Developmental/reproductive toxicity of AN in humans is very limited. A reported
10 decreased testosterone level in AN factory workers (Ivanescu et al., 1990) was confounded by
11 concurrent exposure to other chemicals. No adverse effect was detected for gynecological health
12 of 410 women occupationally exposed to AN (no exposure terms) compared to 436 unexposed
13 women (Dorodnova, 1976). Czeizel et al. (1999) reported on the rate and type of congenital
14 abnormalities in 46,326 infants born to mothers living within a 25 km radius of an AN factory in
15 Hungary. Significant clusters of pectus excavatum (depressed sternum), undescended testes, and
16 clubfoot were noted. The authors, however, reported that the overall results supported the null
17 hypothesis for AN-induced effects in people living in the vicinity of the AN factory.

18 19 **2.4. Genotoxicity**

20 **2.4.1. *In Vitro* Studies**

21
22 In experiments with human lymphocytes, Perocco et al. (1982) showed that exposure of
23 human lymphocytes to 0.5 mM AN (26.5 µg/ml) resulted in a significant increase in SCE. Obe
24 et al. (1985), however, was unable to demonstrate SCE-induction by AN in human lymphocytes
25 exposed for 24 hours to AN at concentrations of 1 or 10 µg/ml in the absence of S9 and for one
26 hour in the presence of S9 from Arochlor-induced rat livers.

27
28 Rizzi et al. (1984) examined the incorporation of [³H]TdR into DNA in HeLa cells. The
29 test groups included a control and AN-treated cells without hydroxyurea (-HU), and control and
30 treated cells treated with hydroxyurea (+HU). The -HU/+HU relationship between treated and
31 control cells and the value of +HU between treated and control cells were statistically
32 significant at AN dose levels of 0.18 (p < 0.01) and 0.036 mM (p < 0.09). It was concluded that
33 AN is mutagenic and genotoxic at very low concentrations. Contrary to this, Martin and
34 Campbell (1985) failed to demonstrate unscheduled DNA repair in HeLa cells.

35
36 AN produced positive results in tests with human lymphoblasts (TK6, *TK* locus) both
37 with and without metabolic activation (Crespi et al., 1985). Tests were conducted at AN
38 concentrations of 5 - 50 µg/ml for three hours in the presence of S9 (from Arochlor-induced rat
39 livers) or for 20 hours without S9. There was a 3.5-fold increase in mutational frequency
40 in the presence of S9 at 40 and 50 µg/ml. In the absence of S9, mutational frequency was
41 increased 2-fold at 15 µg/ml and 1.3-fold at 20 µg/ml (compared to controls).

42
43 Crespi et al. (1985) also conducted tests using the AHH-1 cell line (HGPRT locus).
44 Concentrations of AN were 5 - 25 µg/ml for 28 hours. Tests were conducted with metabolic
45 activation and an expression period of 6 days. An approximate 4.5-fold increase in mutation
46 frequency at 25 µg/ml was detected relative to controls which was similar to the response
47 obtained with the benzo(a)pyrene (3.1 µg/ml) positive control.

48

1 The mutagenic potential of both AN and its metabolite 2-CEO (2-cyanoethylene oxide)
2 was examined using the TK human lymphoblast cell line (with and without S9) with
3 heterozygous thymidine kinase (*tk*) locus as the marker (Recio et al.,1989). Cells were exposed
4 for two hours with an expression period of 6-8 days. AN was not mutagenic in the absence of S9
5 (less than a 2-fold increase in mutation frequency) over a concentration range of 0.4 to 1.5 mM
6 (21 to 80 µg/ml). With S9, there was a statistically significant ($p < 0.05$) 4-fold mutagenic
7 response with the highest exposure concentration 1.5 mM (74 µg/ml). Survival was only 10% at
8 a concentration of 1.5 mM. The metabolite produced a 17-fold increase in mutation frequency
9 without S9 at 100 µM. The results indicated AN to be weakly mutagenic in mammalian cells,
10 while the mutagenic response induced by CEO suggests that it may be the primary mutagenic
11 metabolite of AN. In a follow-up study (Recio et al., 1990), human TK6 lymphoblasts were
12 treated with CEO (150 µM for 2h). Base-pair substitution mutations and frameshift mutations
13 were observed.
14

15 Sister chromatid exchange (SCE) and the induction of DNA single breaks was examined
16 using adult human bronchial epithelial cells (Chang *et al.*, 1990). The cultures were exposed
17 for 20 hours to 150, 300, 500, or 600 µg/ml An and assessed for SCE and DNA strand breaks.
18 Notable cytotoxicity was observed at 600 µg/ml, but not at the lower concentrations. SCEs
19 were significantly increased ($p < 0.01$) at 150 and 300 µg/ml; incidence of SCE per cell was 6.6
20 and 10.7 respectively (3.7 in unexposed controls). The extent of DNA single strand breaks
21 appeared to be positively correlated with AN concentrations.
22

23 A human mammary epithelial cell (HMEC) DNA repair assay in secondary
24 cultures of HMEC was reported by Eldridge et al. (1992). The cultures of normal HMEC
25 were derived from mammoplasties of five healthy women. Although CEO was cytotoxic to
26 HMEC, a positive UDS response was produced thereby confirming its genotoxicity. AN
27 exhibited considerable cytotoxicity but no genotoxicity was observed in the HMEC DNA repair
28 assay.
29

30 **2.4.2. *In Vivo* Studies**

31
32 Chromosomal damage in peripheral lymphocytes of 18 workers exposed to AN for an
33 average of 15.4 years was studied by Thiess and Fleig (1978). The workers were also exposed to
34 styrene, ethylbenzene, butadiene, and butylacrylate. The actual AN exposure was not reported.
35 Air concentrations of AN over approximately 10 years averaged 5 ppm and were reportedly
36 representative of normal operating conditions. During the actual conduct of the study workplace
37 AN levels were about 1.5 ppm. The frequency of chromosomal aberrations in peripheral
38 lymphocytes of the workers was not increased compared to the unexposed controls.
39

40 Borba et al. (1996) reported chromosomal aberrations and SCEs in 14 workers employed
41 in the polymerization area and in 12 maintenance workers of an acrylic fiber plant. A control
42 group consisted of 20 unexposed workers in administration jobs. No AN exposure concentration
43 or exposure duration terms were provided. No difference in SCEs was detected when the
44 exposed groups and the controls were compared.
45

2.5. Carcinogenicity

Numerous studies have been conducted to assess the potential carcinogenicity of AN. These have been previously reviewed (Felter and Dollarhide, 1997; Sapphire Group, Inc., 2004). Because a carcinogenic response is unlikely following a single acute once-in-a-lifetime exposure, an extensive review of the available information on this subject is considered beyond the scope of this document.

Following extensive analysis of the epidemiology studies (occupational cohort studies, supporting cohort and case-control studies), it has been concluded that many of the older studies had methodological or design weaknesses (e.g., insufficient sample size, insufficient or incomplete follow-up, inadequate exposure assessment, confounding factors such as simultaneous exposures and smoking habits for which there were no controls) and that the results of the studies did not provide adequate evidence that AN is carcinogenic in humans at current occupational exposure levels or at lower levels that would be characteristic of environmental exposures (Sapphire Group, Inc., 2004). In the evaluation it was also noted that results of more recent studies (Benn and Osborne, 1988; Blair et al., 1988; Wood et al., 1988; Swaen et al., 1998, 2004) supported this conclusion and that meta-analysis (Rothman, 1994; Collins and Acquavella 1998, EU, 2001) affirmed that cancer risk associated with AN exposure is extremely low.

Felter and Dollarhide (1997) concluded that the human weight of evidence for the carcinogenicity of AN is insufficient. Evaluations of recent literature indicate that the weight of evidence from human studies does not support the conclusion that there is a causal association between exposure to humans and lung cancer. A 1×10^{-4} risk specific concentration of 9 F g/m^3 was derived based upon the LED_{10} .

The disparity between findings from laboratory animal bioassays and human epidemiological findings was evaluated by Ward and Starr (1993). According to the US EPA estimates derived from animal studies (based on USEPA's potency estimates from their 1983 assessment), lifetime exposure to $1 \text{ } \mu\text{g/m}^3$ AN translates into an increased cancer risk of 1 in 6,700 people (6.7×10^{-3}) and into an increased risk of brain cancer of 1 in 12,000 people (1.2×10^{-4}). Assuming that workers in older studies were exposed to an average level of 2 to 5 ppm AN during their working lifetime, they determined the statistical power of the AN epidemiological studies was high enough (>80%) to reliably detect the USEPA predicted increases of cancer due to occupational AN exposure. However, these predicted increases were not found in any of the epidemiological studies. The authors concluded that the upper bound estimate of the AN inhalation cancer potency as estimated by the USEPA was too high to be consistent with the human experience in occupational exposure situations.

IARC downgraded AN from a category 2a to a category 2b (IARC, 1999). This status change was based upon the lack of carcinogenic evidence from the more recent epidemiological studies. The data regarding potential carcinogenicity of AN in humans is considered to be inadequate and no evidence of a causal association exists. This decision supports the conclusion that AN is probably not carcinogenic to man.

2.6. Summary

A concentration range of 1.6 - 36.3 ppm has been reported as AN odor thresholds for humans. Nonlethal effects of occupational exposure to AN include headache, nasal and ocular irritation, thoracic discomfort, nervousness and irritability but definitive exposure-response data are lacking. Available information indicates that such effects resolve following removal from exposure. No signs or symptoms were reported for male volunteer subjects following exposure up to 4.6 ppm for 8 hours. Lethality following acute inhalation exposure to AN has been reported. Although no exposure terms are available and information is limited, children appeared to be more susceptible than adults in the same exposure conditions.

3. ANIMAL TOXICITY DATA

3.1. Acute Lethality

3.1.1. Monkey

Rhesus monkeys (4.2-4.8 kg) were exposed to 65 ppm AN (2 males and 2 females) or to 90 ppm (2 females) for 4 hours (Dudley and Neal, 1942). The AN test atmosphere was generated by bubbling air through AN (purity determined through repeated fractional distillations free of cyanide and with a boiling point of 76-77°C) and mixing this AN-saturated air stream with a main air stream. Air flow through the exposure chamber was 260 L/min (" 2%). The concentration of the AN was varied by adjusting the volume of air passing through the bubbler. The concentration of AN in the chamber was determined by the change in weight of the AN in the bubbler, air flows and start/stop times. Even at the highest exposure (90 ppm), the rhesus monkeys (all individuals in this exposure group) exhibited only slight redness of the face and genitals, and a slight increase in respiratory rate upon initial exposure.

Dudley et al. (1942), exposed four rhesus monkeys to 56 ppm (average concentration) of AN 4 hours/day, 5 days/week for four weeks. All four monkeys survived and showed no evidence of toxicity during the four week exposure period.

3.1.2. Rat

Dudley and Neal (1942) conducted single exposure experiments in which groups of 16 Osborne-Mendel rats (- 295 g, gender not specified) were exposed for 0.5, 1, 2, 4, or 8 hours to various concentrations of acrylonitrile (Table 2). Details regarding generation of the test atmospheres are provided in the preceding paragraph (Section 3.1.1.). Responses included initial stimulation of respiration followed by rapid shallow respiration. Above 300 ppm, rats started exhibiting signs of ocular and nasal irritation. Rats exposed to any concentration of AN exhibited flushing (reddening) of the skin, nose, ears, and feet. Prior to death, the rats were gasping and convulsing. Gross pathology findings of dead rats revealed bright red lungs of "normal consistency" and dark red blood. Rats which survived any acute exposure to AN exhibited no residual effects. Results of the experiments are summarized in Table 2.

TABLE 2. Toxicity of AN Vapor In Rats Exposed for 0.5 to 8 Hours.

Exposure Time (hrs)	Exposure Conc. (ppm)	Mortality (%) During Exposure	Total Mortality (%)	Effects ^a
0.5	2445	0	0	Marked; slight residual effects to 24 hrs
	1490	0	0	Marked; no residual effects in 24 hrs
	1270	0	0	Marked; no residual effects in 24 hrs
	665	0	0	Moderate transitory effects
1	2445	0	81	Deaths in 4 hrs; slight effects at 24 hrs in survivors
	1490	0	25	Deaths in 4 hrs; slight effects at 24 hrs in survivors
	1270	0	0	Marked effects; slight effects at 24 hrs; normal at 48 hrs
	665	0	0	Marked transitory effects
2	1260	0	100	Fatal; deaths within 4 hrs
	595	0	6	Marked transitory effects
	305	0	0	Slight transitory effects
4	635	50	100	Fatal
	315	25	31	Marked; no effects in survivors at 24 hrs
	130	0	0	slight transitory effects
8	320	94	94	Fatal
	270	44	44	Marked; no effects in survivors at 24 hrs
	210	6	6	Marked transitory effects
	135	0	0	Moderate transitory effects
	90	0	0	Slight discomfort

^aNonlethal effects included initial rapid respiration followed by rapid shallow breathing; prior to death animals exhibited slow, gasping respiration, convulsions, followed by coma. Dudley and Neal, 1942.

1
2
3
4
5
6
7

In another phase of the study by Dudley and Neal (1942), rats (16/group) were exposed for 4 hours to 635, 315, 130, or 100 ppm (Table 3). Exposure to 130 ppm slight transient effects and no lethality. Effects were similar to those described in the preceding paragraph. Exposure to 315 ppm resulted in 31% mortality and exposure to 635 ppm produced 100% mortality.

TABLE 3. Toxicity of AN Vapor in Rats Exposed For 4 Hours.

Exposure Conc. (ppm)	Mortality (%) During Exposure	Total Mortality (%)	Effects
635	50	100	Death occurred in 2-6 hrs
315	25	31	Marked effects; no residual effects in survivors
130	0	0	Slight transitory effects
100	0	0	Slight transitory effects

Dudley and Neal, 1942

8
9

In a lethality study conducted at Haskell Laboratory (du Pont & Co., 1968), groups of adult male ChR-CD rats (248-268 g) were exposed to AN for 4 hours. The test chamber atmosphere was analyzed at least every half hour by gas chromatography. Test animals were observed for 14 days. During exposure the rats exhibited irregular respiration, hyperemia, lacrimation, tremors, convulsions. Deaths occurring during exposure occurred within 2-4 hours after the start of the exposure. Deaths occurring after exposure occurred between 7 minutes and 18 hours. A 4-hr LC₅₀ of 333 ppm (275-405 ppm 95% confidence interval) was reported. Rats surviving the exposure exhibited mild to severe, dose-related weight loss the first day of observation followed by normal weight gain.

19

1 Appel et al. (1981a) provided lethality data for groups of 3 to 6 male Wistar rats exposed
 2 to AN for 30-180 minutes with exposure concentration varying with exposure duration
 3 (Table 4). In this study (designed to assess potential antidotes for acute AN toxicity), AN vapor
 4 was generated by evaporating AN (99.5% purity) in a halothane vaporator and adjusting the AN
 5 vapor concentration with clean filtered air. Vapor concentration was determined by gas
 6 chromatography.
 7

TABLE 4. Lethal Response of Rats Exposed to AN at Various Exposure Concentration/Durations.

Exposure conc. (ppm)	Exposure duration (min)	Mortality ratio
650	180	1/3
950	120	1/3
1100	120	3/3
1600	30	0/3
2600	30	1/3
3000	30	6/6
2400	10	0/3

8 Appel et al. (1981a).
 9

10 In a rat study reported by Vernon et al. (1990), a group of 10 adult Sprague-Dawley rats
 11 (5/gender) was exposed for 1 hour to 1,080 ppm AN. None of the rats died. Clinical signs
 12 reported included rapid shallow breathing, decreased activity, nasal discharge, salivation,
 13 lacrimation and coma (in 3 of 10 animals). The extremities of all animals were red at 37 minutes
 14 into the exposure. All rats recovered within five minutes of exposure termination.
 15

16 A GLP-OECD guideline study sponsored by the Shanghai SECCO Petrochemical
 17 Company, Ltd. examined the acute toxicity of AN in rats (WIL Research Laboratories, 2005). In
 18 this study, groups of 5 male and 5 female CrI:CD[®](SD) rats (8-12 weeks old; 242-297 g) were
 19 exposed (nose-only) for 4 hours to 539, 775, 871, 1006, or 1181 ppm AN (99.9 % purity). The
 20 rats were acclimated for 7 days prior to exposure and observed for 14 days after exposure.
 21 Exposure was in a two-tiered conventional nose-only exposure system where exposure
 22 atmosphere conditions (temperature, oxygen, humidity, etc.) were monitored every 20-30
 23 minutes. The AN test atmosphere was generated by passing compressed nitrogen through the
 24 test material to create a vapor which was diluted with compressed air prior to being delivered to
 25 the exposure system. Actual AN concentrations were determined by gas chromatography.
 26 Mortality data are summarized in Table 5. The report provided 4-hour LC₅₀ values of 964 ppm
 27 (857-1085 95% c.i) for males, 920 ppm (807-1050 95% c.i) for females, and 946 ppm (866-
 28 1032 95% c.i.) combined (determined by the method of Litchfield and Wilcoxon, 1949).
 29
 30

TABLE 5. Lethality in rats following nose-only inhalation exposure to AN for 4 hours

Exposure Conc. (ppm)	Mortality During Exposure		Total Mortality		Comments
	M	F	M	F	
539	0	0	0	0	
775	0	0	0	0	
871	0	0	1	3	Deaths at 0 to 1 day postexposure
1006	1	1	3	4	2 (0 , 3 (0)) at 0 to 1 day postexposure
1181	4	3	5	4	1 (0 , 1 (0)) at 0 to 1 day postexposure

WIL Research Laboratories, 2005

Clinical observations immediately following exposure included tremors, ataxia, labored respiration, hypoactivity, decreased defecation, and gasping but there was no apparent exposure concentration-effect relationship. Necropsy findings in dead rats included the presence of a distended, gas-filled jejunum in one female of the 871-ppm group, distended gas-filled stomach in three females in the 871-ppm and 1006-ppm groups, and dark, discoloration of the lungs in one male and one female in the 1181-ppm group. No other findings were noted for rats that died. At scheduled sacrifice, the only finding was dark discoloration of the lungs in one male of the 871-ppm group.

3.1.3. Dog

In their assessment of AN lethality in multiple species, Dudley and Neal (1942) also exposed groups of 2-4 male and female dogs (5.5-12.0 kg; strain not specified) to various AN concentrations for 4 hours (Table 6). The investigators found dogs to be more sensitive to inhaled AN; exposures producing only minor effects in other species caused coma and death in the dogs.

Exposure Conc. (ppm)	Gender	Effects
30	F	Slight salivation by end of exposure period; no other effects
	F	Slight salivation by end of exposure period; no other effects
	F	Slight salivation by end of exposure period; no other effects
	F	Slight salivation by end of exposure period; no other effects
65	F	Severe salivation; weak by end of exposure
	F	Coma by end of exposure; died at 8 hrs
100	M	Severe salivation during exposure; full recovery within 24 hrs
	F	Convulsions at 2.5 hrs; coma by end of exposure; partial paralysis of hind legs for 3 days
	F	Convulsions at 2.5 hrs; coma by end of exposure; full recovery within 48 hrs
110	F	Coma at end of exposure; dead at 4.5 hrs
	M	Coma at end of exposure; dead at 3 days
	F	Coma at end of exposure; food refusal for 10 days; slowly recovered
165	F	Convulsions at 2 hrs; dead at 3 hrs of exposure
	M	Coma from end of exposure to death at 4 hrs.

Dudley and Neal, 1942

Results of a 4-week repeat exposure experiment using two dogs exposed to an average concentration of 56 ppm AN for 4 hours/day was reported by Dudley et al. (1942). After the first four hour exposure, one dog died in convulsions while the second dog developed a transient paralysis of the hind legs after the 5th, 13th and 14th exposure. Subsequent exposures were well tolerated.

3.1.4. Guinea pig

Results of 4-hour exposure experiments with guinea pigs (8-16 per group; - 695 g) are shown in Table 7 (Dudley and Neal, 1942). Neither redness of the skin nor eyes was observed in guinea pigs as it was in other species. Exposure to AN did cause watering of the eyes, nasal discharge, and coughing. As exposure increased, coughing was accompanied by moist breath

sounds. Exposures that were lethal in dogs had very little effect on guinea pigs. Delayed death (3-6 days post exposure) was attributed to pulmonary edema.

Exposure Conc. (ppm)	Mortality (%) During Exposure	Total Mortality (%)	Effects
100	0	0	Slight to no effect
265	0	0	Slight transitory effect; reduced feed consumption for 4 days
575	25	63	Ocular and nasal irritation during exposure; delayed death (3-6 days) probably from pulmonary edema
1160	13	100	5 Dead within 1.5 hrs post exposure; 2 dead at 18 hrs

Dudley and Neal, 1942

3.1.5. Cat

In the study by Dudley and Neal (1942), groups of 2-4 cats (gender not specified; - 3.6 kg) were exposed to AN for 4 hours. Exposure to 100 ppm produced only salivation and slight transient effects (redness of the skin and mucosae) while exposure to 275 ppm resulted in more severe effects (marked salivation, signs of pain) but no deaths. At 600 ppm, 100% mortality (preceded by convulsions) occurred within 1.5 hour following exposure.

Four cats were exposed to 56 ppm AN (average concentration) 4 hours/day, 5 days/week for 8 weeks (Dudley et al., 1942). The cats occasionally vomited, were lethargic, and lost weight. One cat developed a transitory weakness of the hind legs after the 3rd exposure and died after the 11th exposure. The remaining three cats survived the entire exposure period with minimal effects.

3.1.6. Rabbit

In the Dudley and Neal (1942) report, groups of 2-3 albino rabbits (gender not specified; - 4.5 kg) were exposed to AN for 4 hours. Signs of exposure were similar to those observed for rats but the rabbits appeared to be more susceptible to AN-induced lethality. Exposure to 100 or 135 ppm produced slight to marked transitory effects. Exposure to 260 ppm killed 1 of 2 rabbits during exposure while the second died within 4-5 hours. Exposure to 580 ppm resulted in a similar response with the second rabbit dead within 3-4 hours.

In an 8-week repeat exposure study, three rabbits were exposed for 4 hours/day, 5 days/week to 100 ppm AN (average concentration) (Dudley et al., 1942). The rabbits survived for the full exposure duration, but were drowsy and listless during exposure and gained no weight gain. No additional effects were observed.

3.2. Nonlethal Toxicity

3.2.1. Monkey

No evidence of toxicity was observed in rhesus monkeys (four per group; gender not specified) exposed to 56 ppm AN (126 mg/m³) four hours/day, five days/week for 4-weeks

1 (Dudley et al., 1942). A slight increase in respiration upon initial exposure was the only effect
2 reported for 2 male and 2 female monkeys exposed for 4 hours to 65 ppm AN (Dudley and Neal,
3 1942). In the same study, two female monkeys exposed to 90 ppm AN for 4 hours exhibited
4 slight weakness, redness of the face and genitals, and a slight increase in respiratory rate. These
5 effects resolved within 12 hours post exposure. Details regarding generation of the test
6 atmospheres are provided in Section 3.1.1.

8 **3.2.2. Dog**

10 In a preliminary investigation into the toxicity of AN (Haskell Laboratory, 1942),
11 exposure of 3 dogs (strain, gender, age, weight not specified) for 6 hours to 25 ppm AN caused a
12 rise in body temperature of at least 2EF. Exposure to 50 ppm resulted in a drop in body
13 temperature of as much as 1.6EF. Three dogs were exposed for 1.75 hours to 225 ppm AN.
14 Two of three dogs exhibited an initial marked increase in pulse rate followed by a decrease.
15 Blood pressure increased in 2 of 3 dogs and decreased in a third dog. Overt signs of exposure
16 included ocular and nasal irritation, vomiting, incoordination, and “noisy” respiration. All dogs
17 recovered within 24 hours.

19 Four dogs exposed to 30 ppm for 4 hours showed only slight salivation (Dudley and
20 Neal, 1942). Severity of effects increased with increasing concentration. Exposure to 65 ppm
21 produced weakness in one dog and coma in another while exposure to 100 ppm resulted in
22 convulsions in two of three dogs (see Table 6, Section 3.1.4). All of the dogs in these exposure
23 groups fully recovered within 48 hours or less. Details regarding generation of the test
24 atmospheres for these experiments are described in Section 3.1.1.

26 **3.2.3. Cat**

28 In the study by Dudley and Neal (1942), groups of 2-4 cats (gender not specified; - 3.6
29 kg) were exposed to 100 ppm AN for 4 hours exhibited only salivation and slight transient
30 effects (redness of the skin and mucosae) while exposure to 275 ppm resulted in more severe
31 effects (marked salivation, signs of pain) but no deaths.

33 **3.2.4. Rat**

35 Dudley et al. (1942) exposed 16 rats to an average concentration of 100 ppm AN
36 5 days/week for 8 weeks. Slight lethargy during exposure was the only adverse effect observed.
37 During the test period, 3 of the 7 females gave birth and raised normal litters.

39 Results of a study by Bhooma et al. (1992) study demonstrated fibrin network formation
40 in the lung of 6 male Wistar rats exposed to 100 ppm AN 5 hours/day for 5 days and observed
41 for 28 days. Alveolar macrophage activity was elevated from post exposure day 1 to day 14 and
42 returned to normal by day 28. Procoagulant activity in lavage fluid was unaltered for the first 5
43 days but elevated when assessed at days 14 and 28.

45 In the Dow Chemical study (Quast et al., 1980) study, rats exposed 6 hours/day, 5
46 days/week to 80 ppm AN exhibited “minimal changes microscopically in the respiratory
47 epithelium of the nasal turbinates of 80 ppm rats suggestive of slight degree of irritation” at the
48 6- month interim sacrifice interval. There was no mention of adverse effects associated with the
49 20-ppm exposure.

1
2 In the study by WIL Research Laboratories (2005), vocalization upon handling was
3 reported for rats exposed (nose-only) to 539 ppm for 4 hours. Some rats exposed to 775 ppm
4 exhibited ataxia, labored breathing, hyperactivity, and decreased urination and defecation during
5 or after exposure. The rats in both groups were normal within 2 days (539-ppm group) or 8 days
6 (775-ppm group) after exposure.
7

8 **3.2.5. Rabbit**

9

10 In the Dudley and Neal (1942) report, groups of 2-3 albino rabbits (gender not specified;
11 - 4.5 kg) exposed to 100 or 135 ppm AN for 4 hours produced slight to marked transitory effects
12 in respiratory pattern and signs of irritation.
13

14 **3.2.6. Guinea pig**

15

16 Dudley et al. (1942) also exposed 16 guinea pigs to an average concentration of 100 ppm
17 AN days/week for 8 weeks. The guinea pigs gained weight moderately and exhibited slight
18 lethargy during the exposure but no other adverse signs were observed.
19

20 **3.3. Developmental/Reproductive Effects**

21

22 In a developmental toxicity study conducted by Murray et al. (1978), groups of 30
23 pregnant Sprague-Dawley rats were exposed to 0, 40, or 80 ppm AN (>99 purity) 6 hrs/day on
24 gestation days 6 through 15. The exposure levels were selected based upon the TLV (20 ppm)
25 and preliminary results of a long-term inhalation toxicity study. Clinical signs (daily), maternal
26 body weight, feed consumption were monitored and gross necropsies were performed. Standard
27 developmental parameters were assessed. Gender and body weight, external abnormalities and
28 skeletal and soft-tissue anomalies of fetuses were evaluated. The rats were exposed in stainless
29 steel and glass Rochester type chambers (4.3 m³) with dynamic airflow conditions. The AN
30 vapor was generated by metering AN into an airstream. The test atmosphere was analyzed by
31 gas-liquid chromatography three times per day. Time-weighted mean concentrations of AN
32 were 40" 2 and 77" 8 ppm (mean " s.d.)
33

34 Results of the Murray et al. (1978) study are summarized in Tables 8, 9, and 10. No
35 treatment-related signs of toxicity were observed during the exposure period. Mean body weight
36 and maternal body weight gain was significantly decreased during treatment in both dose groups.
37 Relative to controls, food consumption was decreased during gestation days 15-17 but increased
38 on days 18-20. Maternal liver weight was unaffected by AN exposure. Pregnancy incidence,
39 mean litter size, incidence of resorptions and average fetal body measurements were unaffected
40 by exposure to AN. A significant (p<0.06) increased incidence of total malformations was
41 detected for litters from the 80-ppm group. Specific malformations included short tail, short
42 trunk, missing ribs, delayed ossification of skull bones, omphalocele and hemivertebrae;
43 observed only in the 80 ppm treatment group. Although the incidence of malformations was not
44 statistically increased compared to the control group, these high-dose effects were considered to
45 be exposure-related, because of similar findings in a gavage study by Murray et al. (1976). The
46 investigators concluded that the data suggested a teratogenic effect of AN at 80 ppm but that
47 there was no evidence of teratogenicity or embryotoxicity in rats exposed to 40 ppm.
48

Parameter	Exposure concentration		
	0 ppm	40 ppm	80 ppm
No. deaths/no. females	0/40	0/38	0/40
% pregnant (no.)	88 (35)	97 (37)	90 (36)
Additional pregnancies (detected by stain)	0	0	0
Body weight gain of dams	19" 5	1" 6*	-5" 10*
g.d. 6-9	43" 8	32" 14*	31" 17*
g.d. 10-15	82" 12	84" 22	92" 15
g.d. 16-20			
Liver weight (g.d. 21)	16.0" 1.8	15.9" 1.8	15.3" 1.6
Abs. (g)	38.6" 2.9	41.3" 3.1	40.3" 4.3
Rel. to b.w. (g/kg)			

* p<0.05

Murray et al., 1978

1
2

Parameter	Exposure concentration		
	0 ppm	40 ppm	80 ppm
No. of litters	33	36	35
Implantations/dam	13" 2	13" 2	12" 3
Live fetuses/litter	13" 2	12" 2	12" 3
Resorptions/litter	0.6" 0.7	0.7" 1.1	0.5" 0.6
Fetal b.w. (g)	5.79" 0.33	5.72" 0.42	5.90" 0.25
Fetal crown-rumplength (mm)	43.9" 2.1	43.5" 2.2	43.7" 2.2

Murray et al., 1978

3

Parameter	Exposure concentration		
	0 ppm	40 ppm	80 ppm
No. fetuses/No. litters examined			
External & skeletal malformations	421/33	441/36	406/35
Visceral malformations	140/33	148/36	136/35
No. fetuses (litters) affected			
External malformations			
Short tail	0(0)	0(0)	2(2)
Short trunk	0(0)	0(0)	1(1)
Imperforate anus	0(0)	0(0)	0(0)
Omphalocele	0(0)	1(1)	1(1)
Visceral malformations			
Right-sided aortic arch	0(0)	0(0)	0(0)
Missing kidney, unilateral	0(0)	0(0)	0(0)
Anteriorly-displaced ovaries	0(0)	0(0)	1(1)
Skeletal malformations			
Missing vertebrae (associated with short tail)	0(0)	2(1)	2(2)
Missing two vertebrae and a pair of ribs	8(1)	2(1)	7(2)
Hemivertebra	0(0)	0(0)	1(1)
Total malformed	8(1)	3(2)	11(6)*

*p<0.06

Murray et al., 1978

In a comparative study of the relative reproductive/developmental toxicities of aliphatic mononitriles, Saillenfait et al. (1993a) exposed groups of 20-23 pregnant Sprague-Dawley rats to 0, 12, 25, 50 or 100 ppm AN (>99% purity) by inhalation for 6 hrs/day on gestation days 6 through 20, and euthanized on day 21. Clinical signs of toxicity, maternal body weight, and feed consumption were monitored, and gross necropsies were performed. Fetal examinations included gender ratio and body weight, external abnormalities and skeletal and soft-tissue anomalies. The rats were exposed to the test article in 200 liter stainless steel chambers (23 EC, 50% rel. humidity) with dynamic and adjustable laminar air flow (10-20 m³/hr). The AN vapor was generated by bubbling air through a flask containing AN, the concentration in the chamber being calculated from the ratio of the amount of AN vaporized to the total chamber air flow during the test period. Concentration of AN was determined analytically by hourly sampling and gas-liquid chromatography.

There were no maternal deaths, but a concentration-dependent decreased absolute body weight gain was observed (significant at p<0.01 at three highest dose groups; 25.1g, 16.1 g, -0.1 g, -7.8 g, and -24.3 g, respectively for the 0, 12, 25, 50, and 100 ppm groups). There was no adverse effect on pregnancy rate, average number of implantations or number of live fetuses, incidences of non-surviving implants and resorptions, or fetal sex ratio (Table 11). A statistically significant (p<0.01 to 0.005; see Table 11) exposure-related reduction in fetal weights was observed at 25 ppm and higher concentrations. Evaluation of external, visceral and skeletal variations in the fetuses revealed no AN-related effects. The NOAEL for maternal and developmental toxicity was 12 ppm based on the absence of fetal body weight effect.

TABLE 11. Reproductive parameters in rats exposed to acrylonitrile (AN) vapor on gestation days 6-20.

Parameter	0 ppm	12 ppm	25 ppm	50 ppm	100 ppm
No. deaths of treated females	0/20	0/21	0/21	0/20	0/21
% Pregnant at euthanization	100.0	95.2	95.2	90.0	90.5
No. examined litters	20	20	20	18	19
Implantations sites ^a	13.65" 2.81	14.80" 1.99	14.40" 3.38	15.11" 2.00	14.37" 2.17
Live fetuses/litter ^a	12.30" 4.09	14.00" 2.18	13.85" 3.26	14.50" 1.89	13.63" 2.22
% Non-surviving implants/litter ^a	10.40" 22.75	5.44" 7.38	3.49" 6.10	3.89" 5.37	4.94" 8.33
% Resorption sites/litter ^a	10.40" 22.75	5.11" 6.46	3.49" 6.10	3.89" 5.37	4.94" 8.33
Fetal sex ratio (M:F) %	1.05	0.96	1.23	1.10	0.96
Fetal b.w	5.95" 0.28	5.79" 0.28	5.64" 0.36**	5.54" 0.24**	5.04" 0.36**
% &	5.66" 0.36	5.51" 0.27	5.37" 0.28*	5.18" 0.25**	4.90" 0.49**

^a Mean " s.d.

* p<0.05; **p<0.01

Saillenfait et al., 1993a

3.4. Genotoxicity

The genotoxicity of AN in animal test systems has been extensively reviewed (Sapphire Group, 2004). AN has been shown to be weakly mutagenic in *Salmonella typhimurium* but metabolic activation (S9) appears to be required. In *Escherichia coli* and in rodent test systems, metabolic activation is not required, but tends to enhance a weak AN-induced response. Results from most *in vivo* mammalian cell assays (chromosome aberration induction in mouse and rat

1 bone marrow micronucleus, and sister chromatid exchange induction in mice, and induction of
2 dominant lethal mutations in rat and mouse sperm) were negative. However, positive results
3 were detected in a variety of *in vitro* assays although *in vivo* clastogenicity was not
4 demonstrated. In the Sapphire Group assessment, it was suggested that variability in results
5 between *in vitro* and *in vivo* tests for AN-induced chromosomal damage may be a function of the
6 metabolism of AN in intact animals versus that in cultured cells. Specifically, metabolism of 2-
7 cyanoethylene oxide may be less efficient in animals, or there may be rapid detoxification and
8 elimination of 2-cyanoethylene oxide, thereby limiting the interaction with DNA. Considering
9 the positive results for genotoxicity from *in vitro* studies and the generally negative results from
10 *in vivo* studies, the evidence of AN-induced genotoxicity animals is limited.

11 12 **3.5. Carcinogenicity**

13
14 A 12-month cancer bioassay was conducted by Maltoni et al. (1977). In this study
15 groups of 30 male and 30 female rats were exposed by inhalation to 5, 10, 20, or 40 ppm of AN
16 for 4 hours/day, 5 days/week. A group of rats exposed to clean air served as the control group.
17 The rats were observed until death. Body weight was unaffected by the AN exposure. There
18 was statistically significant increase in the percentage of animals with benign and malignant
19 tumors ($P < 0.01$) and malignant tumors alone ($P < 0.01$). The total malignant tumors per 100
20 animals was noted for several treated groups, but lacked a definitive dose-response relationship.
21 There was no increase in Zymbal's gland tumors, extrahepatic angiosarcomas, or hepatomas.
22 Encephalic glioma incidence was increased in rats exposed to 20 ppm (3.3%; 3/60) and 40 ppm
23 (5%; 3/60). Although not statistically significant, this response was considered by the
24 investigators to be of possible biological relevance because the brain was shown to be a target
25 organ in the oral administration part of the study.

26
27 Maltoni et al (1988) also conducted experiments in which groups of 54 breeder female
28 rats (Group I) were exposed to 60 ppm AN 4 hours/day, 5 days/week for 7 weeks followed by 7
29 hours/day, 5 days/week for 97 weeks. A group of 54 untreated breeder female rats served as
30 controls (Group II). Following transplacental exposure in the pregnant rats in the
31 aforementioned group, inhalation exposure of offspring continued at 4 hours/day, 7 days/week
32 for 7 weeks followed by 7 hour/day, 5 days/ week for 97 weeks (Group Ia), or 4 hours/day, 5
33 days/week for 7 weeks followed by 7 hours/day, 5 days/week for 8 weeks (Group Ib). Offspring
34 group size was 67 males and 54 females in the former exposure protocol and 60 of each gender
35 in the latter protocol. The control offspring group (Group IIa) included 158 males and 149
36 females. Percent of animals with malignant tumors was 37% (20/54) in Group I and 15% (9/60)
37 in the Group II (control). For the offspring in group Ia, the percent of animals (males + females)
38 was 54.5%; 66/121) and for Group Ib 33.3% (40/120). For control group II, percent of animals
39 with malignant tumors was 16.7% (10/60) and for Group IIb was 17.9% (55/307).

40
41 In the long-term inhalation study of Quast et al. (1980), Sprague-Dawley (Spartan
42 substrain) rats (100/sex/concentration) were exposed by inhalation to 0 (control), 20 ppm, and 80
43 ppm AN for 6 hours/day, 5 days/week for two years (analytical concentrations were 20.1" 2.1
44 and 79.5" 7.3 ppm' respectively, at the 6-month sacrifice). A control group was exposed to clean
45 air. The groups also included animals for interim sacrifices at 6 months (7/gender/dose) and 12
46 months (13/gender/dose). Hematology, urinalysis, and clinical chemistry assessments were
47 performed at specific intervals. Clinical observations included body weight, mortality, clinical
48 appearance, onset of tumors, and frequency observed palpable tumors. All rats, regardless of
49 time of death, were subjected to gross pathology examinations.

Alterations in the aforementioned clinical observations occurred earliest and with highest frequency in the high dose (80 ppm) group. Non-neoplastic effects for both exposure groups included exposure concentration-related inflammation and degeneration of tissue in the nasal turbinates (mucosa suppurative rhinitis, hyperplasia, focal erosions, and squamous metaplasia of the respiratory epithelium, with hyperplasia of the mucous secreting cells). Mortality rate was significantly increased ($p < 0.05$) during the first year in both male and female rats of the 80 ppm group and for females of the 20 ppm group during the last 10 weeks of the study. The increased mortality for the 20 ppm females was the result of early sacrifice due to benign mammary gland tumors. Although these tumors are known to occur spontaneously and at a high rate in Sprague-Dawley rats, they were observed earlier and at higher frequency in AN-exposed animals. Focal perivascular cuffing and gliosis was reported in the brain of male rats at 20 (2/99; $p < 0.05$) and 80 ppm (7/99 ($p < 0.05$), and 2/100 and 8/100 ($p < 0.05$), respectively, for females in the 20-ppm and 80-ppm groups. There was an increased incidence of brain tumors ($p < 0.05$ for both male and females at the 80 ppm exposure level compared to the controls) identified histopathologically as focal or multifocal glial cell tumors (astrocytomas). Proliferative glial cell lesion incidence was significantly increased in the 80 ppm males only.

Deaths of rats in the Quast et al. (1980) study were often attributable to severe ulceration of the Zymbal's gland or mammary tissue tumors, and suppurative pneumonia (80-ppm group only) resulting from AN-induced pulmonary irritation. The frequency of Zymbal's gland tumors was significantly increased (11/100; $p < 0.05$) in both male and female animals in the 80 ppm group; in females the highest incidence occurred during the 13 to 18 month interval. An incidence of 3/100 was observed in males exposed to 20 ppm (1/100 for controls). No Zymbal's gland tumors were seen in 20-ppm females. Tumor type and incidence data are summarized in Table 12.

Exposure Concentration (ppm)	Zymbals Gland Carcinoma	Tongue Papilloma/ Carcinoma	Mammary Gland Fibroadenoma	Small Intestine Cystadenocarcinoma	Brain astrocytoma
Males					
0	1/100	1/96	-	2/99	0/100
20	3/100	0/14	-	2/20	4/99
80	11/100*	7/89*	-	14/98*	15/99*
Females					
0	0/100	-	79/100	-	0/100
20	0/100	-	95/100*	-	4/100*
80	10/100*	-	75/100	-	17/100*

*Significantly different from control group ($p < 0.05$)
Quast et al., 1980

3.6. Summary

Acute exposure data from tests with various laboratory species (monkey, rat, dog, rabbit, guinea pig, cat) revealed qualitatively similar responses ranging from mild irritation (redness of exposed skin, lacrimation, nasal discharge) and mild effects on ventilation and cardiovascular responses to severe respiratory effects, convulsions, and death. Four-hour exposure to concentrations ranging from 30 to 100 ppm produced little or no effect in all species except dogs

1 which exhibited severe effects at 100 ppm. Results of a recent nose-only exposure study in rats
2 showed that concentrations up to 50 ppm for 6 hours or 225 ppm for 1.75 hours produced only
3 minor transient effects on blood pressure. Lethality in rats appears to occur at cumulative
4 exposure of 1800-1900 ppm-hrs for 0.5 to 6-hour exposure durations, although for nose-only
5 exposures this is notably higher (- 3800 ppm-hrs). Lethality data for various exposure durations
6 and exposure concentrations suggest a near linear relationship (i.e., $n = 1.1$ for $C^n \times t = k$). Death
7 may be delayed especially at the lower limits of lethal exposures. One study provided evidence
8 for teratogenic effects in rats following gestational exposure of dams to 80 ppm but not 40 ppm
9 AN. Another study showed an exposure-related decrease in fetal weight following gestational
10 exposure of dams to 25, 50, or 100 ppm AN; no other reproductive/developmental effects were
11 detected. Results of *in vitro* testing suggest that AN is weakly mutagenic. Results of *in vivo*
12 mammalian cell assays measuring various endpoints were generally negative. Results of
13 inhalation exposure cancer bioassays have shown that AN is carcinogenic in rats. The brain,
14 spinal cord, Zymbal's gland, tongue, nonglandular stomach, small intestine, and mammary gland
15 have all been identified as targets.

17 4. SPECIAL CONSIDERATIONS

18 4.1. Metabolism and Disposition

19
20 Following inhalation exposure, AN will undergo rapid absorption by passive diffusion.
21 Data from 6 human male volunteers exposed to AN (5 or 22 ppm) for 8 hours indicated that
22 about 52% of the inhaled AN was retained (Jakubowski et al., 1987). Approximately 91.5%
23 retention was reported for rats exposed 1800 ppm (3,900 mg/m³) AN with absorption exhibiting
24 a biphasic pattern (Peter and Bolt, 1984). These investigators also reported that rhesus monkeys
25 absorbed nearly all AN after 6 hours.

26
27 Absorbed AN is readily distributed throughout the body. Kedderis et al.(1996) reported
28 detection of AN and 2-cyanoethylene oxide (CEO) in blood, brain, and liver of Fisher F-344 rat
29 three hours after exposure to 186, 254, or 291 ppm. Concentrations of AN and CEO tended to
30 be greatest in the brain than in liver, and decreased rapidly following cessation of exposure.
31 GSH depletion was shown to enhance tissue uptake of AN into brain, stomach, liver, kidney, and
32 blood of GSH-depleted (phorone/buthionine sulfoximine treatment) F-344 rats (Pilon et al.,
33 1988b). GSH depletion, however, resulted in a decrease in total radioactivity recovered in brain,
34 stomach, liver, kidney, and blood and a decrease in the nondialyzable radioactivity (AN-derived)
35 in the same organs. Control rats showed an accumulation of radiolabel which was greatest in
36 brain RNA; no radioactivity was detected in DNA of any organ examined. In the GSH-depleted
37 rats, radiolabel was greater in brain RNA than in that of the liver or stomach, but was only about
38 half that observed in brain RNA of control rats.

39
40 Excretion of AN and its metabolites is primarily via the urine, with feces and exhaled air
41 being minor routes of excretion. AN and its metabolites have been detected in the urine of
42 exposed workers. Perbellini et al. (1998) reported that levels of AN in urine of pre- and post-
43 shift workers were greater than in non-exposed controls.

44
45 At 24 hours after inhalation exposure of male Sprague-Dawley rats to 0, 4, 20, or 100
46 ppm AN for 6 hours, 2-cyanoethylmercapturic acid, 2-hydroxyethylmercapturic acid, and
47 thiocyanate were measured in the urine (Tardif et al, 1987). The relationship between total
48 urinary metabolites and exposure appeared to be linear. A dose-dependent excretion profile was
49 reported for male Wistar rats following inhalation exposure to 1, 5, 10, 50, or 100 ppm AN for 8

1 hours (Müller et al.1987). Cyanoethyl mercapturic acid, S-carboxymethyl cysteine, hydroxyethyl
2 mercapturic acid, and thioglycolic acid were detected as urinary metabolites. The investigators
3 concluded that urinary metabolite profiles may be useful for biological monitoring of industrial
4 exposure. Specifically, unmetabolized AN and the metabolites, cyanoethyl mercapturic acid and
5 thioglycolic acid, were considered important.

6
7 AN toxicity appears to be directly related to its metabolism. Two major metabolism
8 pathways have been described (Dahl and Waruszewski, 1989; Fennell et al., 1991; Kedderis et
9 al., 1993; Burka et al., 1994; Gargas et al., 1995, Sumner et al., 1999). One pathway is
10 conjugation with glutathione and the second is epoxidation by microsomal cytochrome P4502E1
11 which forms CEO. Metabolites from both pathways are subject to additional biotransformation.
12 The glutathione conjugate may form a mercapturic acid which is excreted in urine. CEO is
13 further metabolized via conjugation with glutathione (catalysis with cytosolic GST or
14 nonenzymatically) resulting in additional conjugates and via hydrolysis by microsomal epoxide
15 hydrolase (EH). The secondary metabolites of CEO may also be further metabolized. Cyanide
16 may be generated via the EH pathway and by one of the GSH conjugation products. Cyanide, in
17 turn, is detoxified to thiocyanate via rhodanese-mediated reactions with thiosulfate. Thiocyanate
18 has been detected in the blood and urine of volunteer subjects following exposure to AN (21-51
19 ppm for 30 minutes) (Wilson and McCormick, 1949).

20
21 Vodička et al. (1990) provided data showing that rats exposed for 6 hours to 75, 150, or
22 300 mg AN/m³ (equivalent to 35, 69, and 138 ppm AN, respectively) excreted as thioethers
23 35.0%, 22.7%, and 18.1%, respectively, of the dose within 24 hours. About one-third to one-
24 half of the excretion occurred during the 6-hour exposure.

25
26 Benz and Nerland (2005) reported on the effect of cytochrome P450 inhibitors and
27 anticonvulsants on the toxicity of AN in male Sprague-Dawley rats. Treatment of rats with 1-
28 benzylimidazole and ethanol effectively reduced blood cyanide levels and early seizures in rats
29 given an LD₉₀ subcutaneous dose of AN but did not affect the clonic convulsions that precede
30 death or AN-induced mortality, thereby suggesting that AN is acutely toxic even in the absence
31 of cyanide.

32 33 **4.2. Mechanism of Toxicity**

34
35 The mechanism by which AN causes irritation is unknown. Nasal tissue damage in rats
36 may be related to metabolism of AN by this tissue (Dahl and Waruszewski, 1989). Hematologic
37 effects may be due to AN and CEO hemoglobin adducts (Bergmark, 1997; Fennell et al., 2000)
38 while GSH depletion in red blood cells may result in the oxidation of hemoglobin to
39 methemoglobin (Farooqui and Ahmed, 1983a).

40
41 Generally, the toxic effects following acute inhalation exposure to AN appear to be
42 irritation of the respiratory tract and the metabolism of AN to cyanide. Acrylonitrile-induced
43 neurological effects in laboratory animals appear to involve the parent compound and the
44 cyanide metabolite. The pivotal role cyanide in the acute toxicity of a series of aliphatic nitriles
45 has been clearly demonstrated (Willhite and Smith, 1981). AN-induced convulsions, are likely
46 the result of cyanide resulting from AN metabolism (Ghanayem et al., 1991; Nerland et al.,
47 1989) although results of metabolism studies by Benz and Nerland (2005) suggest that only the
48 early seizures are cyanide-mediated and that severe clonic convulsions preceding death may be
49 due to parent compound as previously described in Section 4.1. Other possible modes of action

1 include inhibition of glyceraldehyde-3-phosphate dehydrogenase, by binding to critical cysteine
2 residues (Campian et al., 2002) and ATP production by cyanide with respect to CNS effects.
3 Additionally, it has been hypothesized that AN-induced oxidative stress may be related to some
4 neurological effects (Fechter et al., 2003).

5
6 Cyanide formation by dams may be responsible, in part, for the developmental toxicity of
7 AN in animals. may be associated with the release of cyanide during maternal metabolism of
8 AN. Saillenfait and Sabate (2000) reported that a series of aliphatic nitriles produced
9 embryotoxicity similar to that observed for sodium cyanide. Saillenfait et al. (1993b) suggested
10 that glutathione depletion may be involved in the embryotoxicity of inhaled AN in rats.

11 12 **4.3. Structure-Activity Relationships**

13
14 Willhite and Smith (1981) demonstrated the importance of the AN metabolite, cyanide,
15 in the lethal response of CD-1 mice following intraperitoneal injections of acetonitrile,
16 propionitrile, acrylonitrile, *n*-butyronitrile, malonitrile, or succinonitrile. In studies on the
17 effects of P450 inhibitors and anticonvulsants, Benz and Nerland (2005) reported that AN
18 appears to have inherent acute toxicity even in the absence of cyanide. With the data available
19 for AN and considering the apparent complexity of AN acute toxicity compared to other nitriles,
20 structure-activity was not used in the derivation of AEGL values.

21 22 **4.4. Species Variability**

23
24 The effects of acute inhalation exposure to AN are qualitatively similar among several
25 animal species (monkey, dog, cat, rat, rabbit, guinea pig). Nerland et al. (1989) categorized the
26 clinical signs of acute inhalation exposure to AN into four stages: 1) an excitatory phase
27 characterized by lacrimation and agitation, 2) a tranquil phase in which cholinergic responses
28 (salivation, lachrymation, urination, defecation) occur, 3) a convulsive stage characterized by
29 clonic seizures, and 4) a terminal stage characterized by paralysis and death. At least some the
30 variability in the toxic response to acrylonitrile may be a function of the cyanide metabolite and
31 activity levels of rhodanese. Drawbaugh et al. (1987) reported dogs to have relatively lower
32 levels of rhodanese and that rats had relatively high levels; overall species variability was about
33 3-fold. Results of experiments by Dudley and Neal (1942) also indicated that the dog was the
34 most sensitive species.

35
36 Species differences in metabolism of AN are notable. Both rats and mice appear to form
37 CEO at a greater rate (1.5-fold and 4-fold, respectively) than humans (Roberts et al., 1991).
38 Although the rate of CEO formation was greater in mice, levels of CEO were only a third that
39 found in rats (Roberts et al., 1991) suggesting difference between these rodent species. The
40 conjugation rate for CEO with GSH is reportedly faster in humans (1.5-fold) than in mice or rats
41 (Kedderis et al., 1995). The hydrolysis of CEO by EH is notably higher in humans and virtually
42 absent in mice and rats (Kedderis et al., 1995). Based upon spectral analysis of AN interaction
43 with microsomal preparations from rats, mice, and humans, Appel et al. (1981b) conclude that
44 rats resemble humans more closely than do mice.

45 46 **4.5. Susceptible populations**

47
48 Due to the pivotal role of oxidative metabolism of AN in the formation of cyanide,

1 alterations in oxidative metabolism capacity (e.g., induction or inhibition of CYP2E1) may
2 affect cyanide production rate (induction resulting in greater cyanide formation). Because
3 cyanide detoxification may be affected by variances in sulfane sulfur as a source for thiocyanate
4 formation via rodanese, individuals with lower circulating levels of sulfane sulfur (e.g., low
5 cysteine content diets) may have lowered capacity for cyanide detoxification. It is the net
6 difference between the capacities of these processes that will ultimately determine the overall
7 cyanide-induced toxicity.
8

9 Results of a study examining the relationship between cigarette smoking, AN-derived
10 hemoglobin adducts (N-(2-cyanoethyl)valine), and null genotypes for glutathione transferase
11 (GSTM1 and GSTT1) were reported by Fennell et al. (2000). Analysis of the GST genotypes
12 (by blood analysis) from 16 nonsmokers and 32 smokers (one to two packs/day) showed that
13 hemoglobin adduct levels increased with increased cigarette smoking dose. Because the GSTM1
14 and GSTT1 genotypes had little effect on adduct levels concentrations, the results suggest that
15 GST polymorphism may not be relevant to assessing susceptibility to AN toxicity.
16

17 **4.6. Concurrent Exposure Issues**

18
19 Concurrent exposure to agents capable of altering CYP2E1 function or glutathione levels
20 may affect the biotransformation of AN and, therefore, its potential toxicity. Data are
21 unavailable to allow for a quantitative adjustment of AEGL values due to potential concurrent
22 exposure issues.
23

24 **5. DATA ANALYSIS FOR AEGL-1**

25 **5.1. Human Data Relevant to AEGL-1**

26
27 Occupational exposure of 16-100 ppm for 20-45 minutes produced headache, nasal and
28 ocular irritation, discomfort of the chest, nervousness and irritability (Wilson, et al. 1948). Such
29 effects are of greater severity than the AEGL-1 tier definition. Occupational exposure to 0.3 to 3
30 ppm for approximately 3 three years produced similar effects (Babanov et al., 1959). Sakurai et
31 al. (1978) reported that workers routinely exposed to approximately 5 ppm AN in an acrylic fiber
32 factory experienced initial conjunctival irritation to which some degree of accommodation
33 occurred. Six informed male volunteer subjects (including the investigators) exposed to 2.3 and
34 4.6 ppm AN for 8 hours reported no symptoms of exposure (Jakubowski et al., 1987). A report
35 of occupational exposures indicated that exposure to AN at 10 ppm or less was without effects
36 while exposure to 12-15 ppm produced ocular irritation and headache regardless of exposure
37 duration (NAC/AEGL pers. communication).
38

39 **5.2. Animal Data Relevant to AEGL-1**

40
41 Dudley et al. (1942) reported that rhesus monkeys exposed to 65 ppm AN for 4 hours
42 exhibited no adverse effects. Nonlethal responses in rats included slight to marked transitory
43 effects upon exposure to 665 ppm for 0.5 or 1 hour, 305 ppm for 2 hours, 130 ppm for 4 hours,
44 and 90 ppm for 8 hours. Four-hour exposure of dogs to 30 ppm, and guinea pigs, cats, and
45 rabbits to 100 ppm resulted in slight to moderate transitory effects. The WIL Research
46 Laboratories report (2005) reported only vocalization upon handling for rats exposed (nose-only)
47 to 539 ppm for 4 hours. Some rats exposed to 775 ppm exhibited ataxia, hyperactivity, and
48 decreased urination and defecation. Other lethality bioassay reports simply indicated some
49 exposures as nonlethal with no details regarding the presence or absence of nonlethal effects.

5.3. Derivation of AEGL-1 Values

The most relevant data for AEGL-1 derivation is the human response data reported by Jakubowski et al. (1987) regarding the absence of effects in volunteer subjects exposed for 8 hours to 4.6 ppm AN. This is consistent with the report by Sakurai et al. (1978) in which workers routinely exposed to approximately 5 ppm AN experienced initial conjunctival irritation and for which there was some accommodation. It is also consistent with more recent occupational exposure data indicating that exposure to 10 ppm was without effect while exposure to 12-15 ppm produced ocular irritation and headache regardless of exposure duration (NAC/AEGL pers. communication). It is reasonable to assume that for AEGL-1 severity effects, individual variability in the response to AN would vary no more than 3-fold, thereby indicating a point-of-departure (POD) of about 5 ppm (3-fold reduction of the 15 ppm concentration from occupational exposure data). Therefore, measured 4.6 ppm reported by Jakubowski et (1987) was considered an appropriate POD for AEGL-1 derivation. This is slightly lower than the no-effect level of 10 ppm noted in the occupational exposure findings but is appropriate for the general public who may not be accustomed to acrylonitrile exposure as would workers. Because occupational exposure data indicated the occurrence and severity of minor effects (ocular irritation and headache) to be independent of exposure duration, the AEGL-1 values were held constant at 4.6 ppm across all exposure durations. In light of results of studies showing only mild effects (headache, nervousness, fatigue, nausea, and insomnia) following subchronic occupational exposure to AN levels possibly as high 10-20 ppm (Wilson et al., 1948; Sakurai et al., 1978), further reduction of the AEGL-1 value by increased uncertainty factor application does not appear warranted. AEGL-1 values are shown in Table 13 and their derivation shown in Appendix A.

Classification	10-min	30-min	1-hr	4-hr	8-hr
AEGL-1	4.6 ppm	4.6 ppm	4.6 ppm	24.6 ppm	4.6 ppm

6. DATA ANALYSIS FOR AEGL-2

6.1. Human Data Relevant to AEGL-2

There are no quantitative exposure-response data regarding AEGL-2 type effects in humans. Occupational exposure studies reported varying levels of irritation and reversible effects.

6.2. Animal Data Relevant to AEGL-2

Results of studies with laboratory species show that AEGL-2 type effects in animals include changes in respiratory patterns, tremors, and convulsions, the severity of which appear to increase immediately prior to death. The onset of most of the more severe effects are usually preceded by varying signs of irritation (salivation, redness of skin, lacrimation). Post exposure observation in multiple species showed qualitatively similar effects and that that even severe effects are often reversible upon cessation of exposure.

The report by Dudley and Neal (1942) provides data for six species (monkey, rat, dog, guinea pig, rabbit, and cat). For rats 0.5-, 1-, 2-, 4-, or 8-hour exposure to 2445, 1270, 305, and 135 ppm AN, respectively, produced reversible effects. Apple et al (1981) provided data for rats showing that 10-minute exposure to 2400 ppm or 30-minute exposure to 1600 ppm was not lethal to rats. Dogs were more sensitive to the effects of AN as demonstrated by convulsions and coma at exposures as low as 65 ppm for 4 hours (Dudley and Neal, 1942). Results of a nose-only experiment with rats showed that 4-hour exposure to 775 ppm was not lethal but details were lacking regarding the attribution of observed effects (tremors, ataxia, labored breathing, hypoactivity, and gasping) to these exposures. For rabbits, 4-hour exposure up to 135 ppm AN produced slight to marked, but reversible, effects (Dudley and Neal, 1942).

6.3. Derivation of AEGL-2 Values

The AEGL-2 values are based upon data from rats (16/group) showing slight transient effects (ocular and nasal irritation) following a 2-hour exposure to 305 ppm (Dudley and Neal, 1942). All effects resolved within 12 hours post exposure. The interspecies uncertainty factor was limited to 3 because a non-human primate is considered a more relevant model than rodents, dogs or cats. The intraspecies uncertainty factor was limited to 3 because the effects associated with acute irritation effects of AN are not likely to vary greatly among individuals and because metabolism may be of limited relevance regarding such effects. Additional uncertainty factor application would also result in AEGL-2 values unacceptably similar to AEGL-1 values that are based upon human exposure data. Time scaling for AEGL-2 specific durations from the 4-hour experimental POD was performed using $C^n \times t = k$, where $n = 1.1$ (ten Berge et al., 1986). Occupational exposure data showed that routine exposure to 10-20 ppm (up to ~2-fold higher than the 8-hr AEGL-2) resulted in complaints of headache, fatigue, nausea, and insomnia (Wilson et al. (1948; Sakurai et al. (1978) which are neither irreversible nor escape-impairing effects. The AEGL-2 values for acrylonitrile are shown in Table 14 and their derivation summarized in Appendix A.

TABLE 14. AEGL-2 Values for Acrylonitrile					
Classification	10-min	30-min	1-h	4-h	8-h
AEGL-2	290 ppm	110 ppm	57 ppm	16 ppm	8.6 ppm

7. DATA ANALYSIS FOR AEGL-3

7.1. Human Data Relevant to AEGL-3

Quantitative exposure-response data in humans regarding the lethality of AN are not available.

7.2. Animal Data Relevant to AEGL-3

Lethality data in multiple laboratory species (monkey, rat, dog, rabbit, guinea pig, cat) are available. Lethality in rats appears to occur at cumulative exposure of 1800-1900 ppm@rs for 0.5 to 6-hour exposure durations, although for nose-only exposures this is notably higher (- 3800 ppm@rs). Lethal response data for monkeys were not available. Dogs were the most sensitive species with lethality in one of two dogs observed following a 4-hour exposure to 65 ppm. However, a 4-hour exposure of 4 dogs to 100 ppm resulted in no deaths while exposure to

1 110 ppm killed 2 of 3 dogs. Data for rats was most extensive. Dudley and Neal (1942)
 2 provided response data for rats exposed for 0.5, 1, 2, 4, or 8 hours. Thirty-minute exposure of
 3 rats to AN levels as high as 2445 ppm were without lethal effect. Exposure to 1270 ppm for 1
 4 hour, 305 ppm for 2 hours, 130 ppm for 4 hours, or 135 ppm for 8 hours did not result in deaths
 5 of any rats (16/group). A four-hour LC₅₀ of 333 ppm was reported for rats (du Pont & Co.,
 6 1968). At higher exposure rats died within 2 to 4 hours into the exposure period while deaths
 7 following exposure occurred between 7 minutes and 18 hours; there was a 14-day observation
 8 period. There were no deaths among 10 rats exposed to 1030 ppm AN for 1 hour (Vernon et al.
 9 1990). A 33% mortality (1 of 3 rats) was reported for exposures of 650 ppm for 180 minutes,
 10 950 ppm for 120 minutes, and 2600 ppm for 30 minutes and no deaths at exposures of 1600 ppm
 11 for 30 minutes or 2400 ppm for 10 minutes (Appel et al., 1981a).

13 7.3. Derivation of AEGL-3 Values

15 The AEGL-3 values were derived using BMCL₀₅ as estimates of lethality thresholds.
 16 Data for 30-minute, 1-, 4-, and 8-hour AEGL-specific exposure periods are available from the
 17 reports by Apple et al. (1981) and Dudley and Neal (1942). A 30-minute BMCL₀₅ of 1784 ppm
 18 was calculated from the Appel et al. (1981a) data. The 1-hr, 2-hr, 4-hr, and 8-hr BMCL₀₅ values
 19 derived from lethality data published by Dudley and Neal (1942) are 1024.4, 491.3, 179.5 and
 20 185.8 ppm, respectively, for rats exposed to various concentrations of AN for 1, 2, 4, or 8 hours.
 21 With the exception of the 4-hour value, the resulting BMCL₀₅ values are relationally consistent
 22 across time and were used to derive corresponding AEGL-3 values. The 4-hr value was not used
 23 due to this inconsistency. Consequently, the 4-hour AEGL-3 was time-scaled using the 8-hour
 24 BMCL₀₅ of 185.9 ppm. Although the dog appeared to be the most sensitive species, the overall
 25 database for rats is more robust thereby justifying use of the rat data. Further justification for
 26 limiting the interspecies uncertainty factor to 3 comes from PBPK models demonstrating that
 27 predicted concentrations of AN and the metabolite CEO in blood and brain were similar in rats
 28 and humans exposed by inhalation. The PBPK model for AN and CEO disposition in humans
 29 utilized human *in vitro* data and scaling from a rat model (Kedderis and Fennell, 1996) that
 30 incorporated major biotransformation and reactivity pathways. These included metabolism of
 31 AN to glutathione conjugates and CEO, reaction rates of AN and CEO with glutathione and
 32 tissue components, and the metabolism of CEO by hydrolysis and glutathione conjugation. For
 33 effects resulting from a single acute exposure, an intraspecies uncertainty factor of 3 may be
 34 considered sufficient for accounting for variability in metabolism-mediated effects. Additional
 35 uncertainty factor application would result in incompatibility between AEGL-3 and AEGL-2
 36 values. The resulting AEGL-3 values are shown in Table 15. and their derivation is summarized
 37 in Appendix A.

Classification	10-min	30-min	1-h	4-h	8-h
AEGL-3	480 ppm	180 ppm	100 ppm	35 ppm	19 ppm

41 8. SUMMARY OF AEGLs

42 8.1. AEGL Values and Toxicity Endpoints

44 A summary of AEGL values is shown in Table 16. The AEGL-1 values are based upon
 45 the absence of effects in male volunteer subjects in a controlled exposure study (Jakubowski et

al., 1987) and occupational exposure data showing ocular irritation and headache at 16-20 ppm. The AEGL-2 values are based upon slight transient effect (ocular and nasal irritation) in rats exposed to 305 ppm AN for 2 hours. The AEGL-3 values were derived based upon an estimated lethality threshold (BMCL₀₅) in rats, the species for which the most lethality data are available.

Classification	10-min	30-min	1-h	4-h	8-h
AEGL-1 (Nondisabling)	4.6 ppm	4.6 ppm	4.6 ppm	4.6 ppm	4.6 ppm
AEGL-2 (Disabling)	290 ppm	110 ppm	57 ppm	16 ppm	8.6 ppm
AEGL-3 (Lethality)	480 ppm	180 ppm	100 ppm	35 ppm	19 ppm

8.2. Comparisons with Other Standards and Guidelines

The AEGL values and existing standards and guidelines for acrylonitrile are summarized in Table 17. The 30-minute AEGL-2 value is consistent with the NIOSH IDLH and the 1-hour AEGL values are consistent with the ERPG values developed by AIHA.

Guideline	Exposure Duration				
	10 min	30 min	1 h	4 h	8 h
AEGL-1	4.6ppm	4.6ppm	4.6 ppm	4.6 ppm	4.6 ppm
AEGL-2	290 ppm	110 ppm	57 ppm	16 ppm	8.6 ppm
AEGL-3	480 ppm	180 ppm	100 ppm	35 ppm	19 ppm
ERPG-1 (AIHA) ^a			10 ppm		
ERPG-2 (AIHA)			35 ppm		
ERPG-3 (AIHA)			75 ppm		
EEGL (NRC) ^b					
PEL-TWA (OSHA) ^c					2 ppm
PEL-STEL (OSHA) ^d					
IDLH (NIOSH) ^e		85 ppm			
REL-TWA (NIOSH) ^f	1 ppm 15 min ceiling				1 ppm
REL-STEL (NIOSH) ^g					
TLV-TWA (ACGIH) ^h					2 ppm*
TLV-STEL (ACGIH) ⁱ					
MAK (Germany) ^j					
MAK Spitzenbegrenzung (Germany) ^k					
Einsatztoleranzwert (Germany) ^l					
MAC-Peak Category (The Netherlands) ^m					4 ppm TWA 10 ppm STEL

^a ERPG (Emergency Response Planning Guidelines, American Industrial Hygiene Association) (AIHA, 1994)

1 The ERPG-1 is the maximum airborne concentration below which it is believed nearly all individuals could
2 be exposed for up to one hour without experiencing other than mild, transient adverse health effects or
3 without perceiving a clearly defined objectionable odor.

4 The ERPG-2 is the maximum airborne concentration below which it is believed nearly all individuals could
5 be exposed for up to one hour without experiencing or developing irreversible or other serious health
6 effects or symptoms that could impair an individual's ability to take protective action.

7 The ERPG-3 is the maximum airborne concentration below which it is believed nearly all individuals could
8 be exposed for up to one hour without experiencing or developing life-threatening health effects.
9

10 ^b EEGL (Emergency Exposure Guidance Levels, National Research Council) (NRC, 1985)
11 is the concentration of contaminants that can cause discomfort or other evidence of irritation or intoxication
12 in or around the workplace, but avoids death, other severe acute effects and long-term or chronic injury.
13

14 ^c OSHA PEL-TWA (Occupational Health and Safety Administration, Permissible Exposure Limits - Time Weighted
15 Average) (OSHA, 1993) is defined analogous to the ACGIH-TLV-TWA, but is for exposures of no more
16 than 10 hours/day, 40 hours/week.
17

18 ^d OSHA PEL-STEL (Permissible Exposure Limits - Short Term Exposure Limit) (OSHA, 1993) is defined
19 analogous to the ACGIH-TLV-STEL.
20

21 ^e IDLH (Immediately Dangerous to Life and Health, National Institute of Occupational Safety and Health) (NIOSH,
22 1996) represents the maximum concentration from which one could escape within 30 minutes without any
23 escape-impairing symptoms, or any irreversible health effects.
24

25 ^f NIOSH REL-TWA (National Institute of Occupational Safety and Health, Recommended Exposure Limits -
26 Time Weighted Average) (NIOSH, 1994) is defined analogous to the ACGIH-TLV-TWA.
27

28 ^g NIOSH REL-STEL (Recommended Exposure Limits - Short Term Exposure Limit) (NIOSH, 1994)
29 is defined analogous to the ACGIH-TLV-STEL.
30

31 ^h ACGIH TLV-TWA (American Conference of Governmental Industrial Hygienists, Threshold Limit Value - Time
32 Weighted Average) (ACGIH, 1997) is the time-weighted average concentration for a normal 8-hour
33 workday and a 40-hour work week, to which nearly all workers may be repeatedly exposed, day after day,
34 without adverse effect. * Acrylonitrile noted as confirmed animal carcinogen with unknown relevance to
35 humans.
36

37 ⁱ ACGIH TLV-STEL (Threshold Limit Value - Short Term Exposure Limit) (ACGIH, 1997) is defined as a 15-
38 minute TWA exposure which should not be exceeded at any time during the workday even if the 8-hour
39 TWA is within the TLV-TWA. Exposures above the TLV-TWA up to the STEL should not be longer than
40 15 minutes and should not occur more than 4 times per day. There should be at least 60 minutes between
41 successive exposures in this range.
42

43 ^j MAK (Maximale Arbeitsplatzkonzentration [Maximum Workplace Concentration], Deutsche
44 Forschungs-gemeinschaft [German Research Association], Germany) (DFG, 1999) is defined analogous to
45 the ACGIH-TLV-TWA.
46

47 ^k MAK Spitzenbegrenzung (Kategorie II,2) [Peak Limit Category II,2] (DFG, 1999) constitutes the maximum
48 average concentration to which workers can be exposed for a period up to 30 minutes, with no more than 2
49 exposure periods per work shift; total exposure may not exceed 8-hour MAK. Cat. III indicates possible
50 significant contribution to cancer risk.
51

52 ^l Einsatztoleranzwert [Action Tolerance Levels] (Vereinigung zur Förderung des deutschen Brandschutzes e.V.
53 [Federation for the Advancement of German Fire Prevention]) constitutes a concentration to which
54 unprotected firemen and the general population can be exposed to for up to 4 hours without any health
55 risks.
56

57 ^mMAC (Maximaal Aanvaarde Concentratie [Maximal Accepted Concentration - Peak Category]) (SDU Uitgevers
58 [under the auspices of the Ministry of Social Affairs and Employment], The Hague, The Netherlands 2000)
59 is defined analogous to the ACGIH-Ceiling.

8.3. Data Adequacy and Research Needs

Data were adequate for the development of justifiable AEGL values. Human data were used for deriving AEGL-1 values and data in monkeys were used for developing AEGL-2 values. A robust data set in rats allowed for derivation of AEGL-3 values.

9. REFERENCES

- ACGIH (American Conference of Governmental Industrial Hygienists). 2005. Threshold Limit Values and Biological Exposure Indices. American Conference of Governmental Industrial Hygienists, Inc. Cincinnati, OH.
- ACGIH (American Conference of Governmental Industrial Hygienists). 1991. Documentation of the Threshold Limit Values and Biological Exposure Indices; Acrylonitrile. American Conference of Governmental Industrial Hygienists, Inc. Cincinnati, OH.
- AIHA (American Industrial Hygiene Association). 1989. Odor thresholds for chemical with established occupational health standards. Amer. Industr. Hyg. Assoc., Akron, OH.
- American Cyanamid Co. 1959. The Chemistry of Acrylonitrile. 2nd ed., p. 14-15, New York
- Appel, K.E., Peter, H., and Bolt, H.M. 1981a. Effect of potential antidotes on the acute toxicity of acrylonitrile. *Int. Arch. Occup. Environ. Health*, 49: 157-163.
- Appel, K.E., Peter, H., Bolt, M., Bolt, H.M. 1981b. Interaction of acrylonitrile with hepatic microsomes of rats and men. *Toxicology Letters* 7: 335-340.
- Babonov, G.P., Kljucikov, V.N., Karajeva, Z. V. 1959. Clinical symptoms of chronic poisoning by acrylonitrile. *Vrach. Delo*. 8: 833-836. (as cited in WHO IPCS, 1983)
- Bader, M. Wrbitzky, R. 2006. Follow-up biomonitoring after accidental exposure to acrylonitrile- Implications for protein adducts as a dose monitor for short-term exposure. *Toxicology Letters* 162: 125-131.
- BASF AG . 1994. Sicherheitsdatenblatt Acrylnitril ST1.
- Benz, F.W., Nerland, D.E. 2005. Effect of cytochrome P450 inhibitors and anticonvulsants on the acute toxicity of acrylonitrile. *Arch. Toxicol.* 79: 610-614.
- Bergmark E. 1997. Hemoglobin Adducts of Acrylamide and Acrylonitrile in Laboratory Workers, Smokers and Nonsmokers. *Chem Res Toxicol* 10: 78-84.
- Bhooma, T., Padmavathi, B., Devaraj, S.N. 1992. Effect of acrylonitrile on the procoagulant activity of rat lung. *Bull. Environ. Conatm. Toxicol.* 48: 321-326.
- Borba, H., Monteiro, M., Proenca, M.J., Chaveca, T., Pereira, V., Lynce, N. and Rueff, J. (1996). Evaluation of some biomonitoring markers in occupationally exposed populations to acrylonitrile. *Teratogenesis, Carcinogenesis, and Mutagenesis* 16, 205-218
- Buchter, A., Peter, H. 1984. Clinical toxicology of acrylonitrile. *G. Ital. Med. Lav.* 6: 83-86.

- 1 Burka, L.T., Sanchez, I. M., Ahmed, E.A., Ghanayem, B.I. 1994. Comparative metabolism and deposition
2 of acrylonitrile and methacrylonitrile in rats. *Arch. Toxicol.* 68, 611-618.
3
- 4 Campian E.C, Cai J, Benz, F.W. 2002. Acrylonitrile irreversibly inactivates glyceraldehyde-3-phosphate
5 dehydrogenase by alkylating the catalytically active cysteine 149. *Chem Biol Interact* 140(3):279-
6 91.
7
- 8 Chang, C.-M., Hsia, M.T.S, Stoner, G.D., Hsu, I.-C. 1990. Acrylonitrile-induced sister-chromatid
9 exchanges and DNA single-strand breaks in adult human bronchial epithelial cells. *Mutation*
10 *Research* 241, 355-360.
11
- 12 Collins, J.J., Cheng, R., Buck, G.M., Zhang, J., Klebanoff, M. et. al. 2003. The feasibility of conducting a
13 reproductive outcome study of Chinese acrylonitrile worker. *J. Environ. Occup. Med.* 1: 29-32.
14
- 15 Crespi, C.L., Ryan, C.G., Seixas, G.M., Turner, T.R., Penman, B.W. 1985. Tests for mutagenic activity
16 using mutation assays at two loci in the human lymphoblast cell lines TK6 and AHH-1. In:
17 Ashby, J., de Serres, F.J., Draper, M., Ishidate Jr., M., Margolin, B.H., Matter, B.E., Shelby,
18 M.D. (Eds.): Evaluation of short-term tests for carcinogens. Report of the International
19 Programme on Chemical Safety's collaborative study on in vitro assays. *Progress in Mutation*
20 *Research*, 5: 497-516.
21
- 22 Czeizel AE, Hegedus S., Timar. L. 1999. Congenital Abnormalities and Indicators of Germinal
23 Mutations in the Vicinity of an Acrylonitrile Producing Factory. *Mutat Res* 427: 105-123.
24
- 25 Dahl, A.R. and Waruszewski, B.A. 1989. Metabolism of organonitriles and cyanide by rat nasal tissue
26 enzymes. *Xenobiotica* 19: 1201-1205
27
- 28 Davis, J.H., Davies, J.E., Americo Rafonnelli, R.S., Reich, G. 1973. Investigation of fatal acrylonitrile
29 intoxications. Pesticides and the environment, a continuing controversy. *Inter. Med. Book Corp.*,
30 2, 547-556.
31
- 32 Delivanova, S., Popovski,P., Orusev, T. 1978. Belpharoconjunctivitis in workers in the manufacture of
33 synthetic polyacrylonitrile fibers. *God. Zb. Med. Fak. Skopje.* 24: 279-282.
34
- 35 Drawbaugh, R.B., Marrs, T.C. 1987. Interspecies differences in rhodanese (thiosulfate sulfurtransferase,
36 EC 2.8.1.1) activity in liver, kidney and plasma. *Comp. Biochem. Physiol.* 86B: 307-310.
37
- 38 Dorodnova, N.S. 1976. Gynecological morbidity and the specific functions of the female body in the
39 chemical manufacture of "nitron". *Gig Tr Prof Zabol* 8: 45-6.
40
- 41 Dudley, H.C. and Neal, P.A. 1942. Toxicology of acrylonitrile (vinyl cyanide). I. Study of the acute
42 toxicity. *J. Ind. Hyg. Toxicol.*, 24 (2): 27-36.
43
- 44 Dudley, H.C., Sweeney, T.R., Miller, J.W. 1942. Toxicology of acrylonitrile. II. Studies of effects of
45 daily inhalation. *J. Ind. Hyg. Toxicol.*, 24: 255-258.
46
- 47 Du Pont & Co. 1968. Acute inhalation toxicity in rats. Haskell Laboratory report, October 21, 1968.
48
- 49 Eldridge, S.R. Butterworth, B.E., Sprankle, C.S., Working, P.K., Bentley, K.S., Hurtt, M.E. 1992.
50 Tissue-specific genotoxic effects of acrylamide and acrylonitrile. *Environ Mol Mutagen (US)*. 20:
51 148-155.
52
- 53 Enikeeva, N.A., Ostrovskaja, R.S., Syso, L.V., Podrez, Z.G., Braginska, L.L., Gvozdov, N.P.,
54 Nesterova, N.E., Musserskaja, A.N., Suzdaltreva, N.A., Efremov, A.M. 1976. Industrial

- 1 hygiene and health status of workers involved in the manufacture of the synthetic fibre Nitron.
2 Zdor. Rab. Nef. Negtehim. prom-sti. 9: 22-25 (Russian).
3
- 4 Farooqui, M.Y.H., Ahmed, A.E. 1983. In vivo interactions of acrylonitrile with macromolecules in rats.
5 Chem. Biol. Interactions 47, 363-371
6
- 7 Felter, S.P., Dollarhide, J.S. 1997. Acrylonitrile: a reevaluation of the database to support an inhalation
8 cancer risk assessment. Reg. Toxicol Pharmacol. 26: 281-287.
9
- 10 Fennell TR, MacNeela J P, Morris R W, Watson M, Thompson C. L.,
11 Bell D A. 2000. Hemoglobin Adducts From Acrylonitrile and Ethylene Oxide in Cigarette
12 Smokers: Effects of Glutathione S-Transferase T1-Null and M1-Null Genotypes. Cancer
13 Epidemiol Biomarkers Prev 9: 705-712.
14
- 15 Fennell, T.R., Kedderis, G.L., Sumner, S.C.J. 1991. Urinary metabolites of
16 [1,2,3-¹³C]acrylonitrile in rats and mice detected by ¹³C nuclear magnetic resonance
17 spectroscopy. Chem. Res. Toxicol. 4: 678-687.
18
- 19 Finney, D.J. 1971. Probit analysis. Cambridge Univ. Press, London.
20
- 21 Gargas, M.L., Anderson, M.E., Teo, S.K.O., Batra, R., Fennell, T.R., Kedderis, G.L. 1995. A
22 Physiologically-Based Dosimetry Description of Acrylonitrile and Cyanoethylene Oxide in the Rat.
23 Toxicol. Appl. Pharmacol. 134: 185-194.
24
- 25 Ghanayem, B.I., Farooqui, M.Y.H., Elshabrawy, O., Mumtaz, M.M., Ahmed, A.E. 1991. Assessment of the
26 acute acrylonitrile-induced neurotoxicity in rats. Neurotoxicology and Teratology 13: 499-502.
27
- 28 Grunsky, F. 1949. Health care and occupational medicine. Ventox and Ventox intoxication. Dtsch. Med.
29 Wochenschr. 74: 1081-1083.
30
- 31 Haber, F.R. 1924. Zur geschichte des gaskrieges [On the history of the gas war]. In:
32 Fuenf Vortraege aus den Jahren 1920-23 [Five lectures from the years 1920-1923]. Berlin, Germany:
33 Verlag von Julius Springer; pp. 76-92.
34
- 35 Haskell Laboratory. 1942. Toxicity of vinyl cyanide. Medical Research Project No. M-97. Haskell
36 Laboratory of Industrial Toxicology, Wilmington, Delaware.
37
- 38 HSDB (Hazardous Substances Data Bank). 2006. Fluorine monoxide. TOXNET Toxicology Data Network.
39 U.S. Natl. Library of Medicine.
40
- 41 Ivanescu, M., Berinde, M., Simionescu, L. 1990. Testosterone in sera of workers exposed to acrylonitrile.
42 Rev. Roum. Endocrinol. 28: 187-192.
43
- 44 Ivanov, V., Rahier, J., Lauwerys. R. 1989. Lipid peroxidation in acrylonitrile-treated rats, evidenced by
45 elevated ethane production. J. Appl. Toxicol. 9: 353-358
46
- 47 Jakubowski, M., Linhart, I., Pielas, G., Kopecky, J. 1987. 2-Cyanoethylmercapturic acid (CEMA) in the urine
48 as a possible indicator of exposure to acrylonitrile. Brit. J. Industr. Med. 44: 834-840.
49
- 50 Kedderis, G.L., Batra, R., Koop, DR. 1993. Epoxidation of acrylonitrile by rat and human cytochromes
51 P450. Chemical research in Toxicology 6, 866-871.
52
- 53 Kedderis, G.L., Batra, R., Turner, M.J. Jr. 1995. Conjugation of acrylonitrile and
54 2-cyanoethylene oxide with hepatic glutathione. Toxicology and Applied Pharmacology 135, 9-17.

- 1
2 Kedderis, G. L., Fennell, T.R. 1996. Development of a Physiologically Based Description
3 of Acrylonitrile Dosimetry. CIIT Activities, Vol 16, No. 1, January, 1996.
4
- 5 Litchfield, J.T.; Wilcoxon, F. 1949. Simplified method of evaluating dose-effect experiments.
6 J. Pharmacol. Exp. Ther. 96: 99-113.
7
- 8 Maltoni, C., Cilberti, A., Di Maio, E. 1977. Carcinogenicity bioassays on rats of acrylonitrile administered
9 by inhalation and by ingestion. Med. Lavoro, 69: 401-411. |
10
- 11 Maltoni, C., Cilberti, A., Cotti, G., Perino, G. 1988. Long-term carcinogenicity bioassay on acrylonitrile
12 administered by inhalation and by ingestion to Sprague-Dawley rats. Ann. New York Acad. Sci.
13 534: 179-202.
14
- 15 Müller, G., Verkoyen, C., Soton, N., Norpoth, K. 1987. Urinary excretion of acrylonitrile and its metabolites
16 in rats. Arch. Toxicol. 60: 464-466.
17
- 18 Murray, F.J., Nitschke, K.D., John, J.A., Crawford, A.A., Murray, J.S., Rampy, L.W.,
19 Schwetz, B.A. 1978. Teratologic evaluation of inhaled acrylonitrile monomer in rats.
20 Toxicological Research Laboratory, Health and Environmental Research, Dow Chemical, USA,
21 Midland, MI.
22
23
- 24 Murray, F.J., Nitschke, K.D., John, J.A., Smith, J.A., Quast, J.F., Blogg, C.D., Schwetz,
25 B.A. 1976. Teratologic evaluation of acrylonitrile monomer given to rats by gavage.
26 Toxicological Research Laboratory, Health and Environmental Research, Dow Chemical, USA,
27 Midland, MI.
28
- 29 NAC/AEGL (National Advisory Committee on Acute Exposure Guideline Levels). 2007. Industry
30 reports of occupational exposure to acrylonitrile. NAC/AEGL Mtg. No. 42, Irvine, CA. March
31 2007.
32
- 33 Nerland, E.E., Benz, F.W., Babiuk, C. 1989. Effects of cysteine isomers and derivatives on acute acrylonitrile
34 toxicity. Drug Metabolism Reviews 20: 233-246.
35
- 36 NIOSH (National Institute for Occupational Safety and Health). 1996. Documentation for Immediately
37 Dangerous to Life or Health Concentrations (IDLHs). Acrylonitrile. U.S. Department of Health and
38 Human Services; U.S. Government Printing Office, Washington. (Retrieved online Sept. 2006.)
39
- 40 NIOSH (National Institute for Occupational Safety and Health). 2005. NIOSH Pocket Guide
41 to Chemical Hazards (2005-151). U.S. Department of Health and Human Services; U.S. Government
42 Printing Office, Washington, PB9419504 National Technical Information Service, Springfield, VA.
43
- 44 NPI (National Pollution Inventory). 2006. Acrylonitrile (2-propenenitrile) fact sheet.
45
- 46 NRC (National Research Council). 2001. Standing operating procedures for developing
47 acute exposure guideline levels for hazardous chemicals. Committee on Toxicology, Board on
48 Toxicology and Environmental Health Hazards, Commission on Life Sciences, National Research
49 Council. National Academy Press, Washington, DC.
50
- 51 NTP (National Toxicology Program). 2006. Report on Carcinogens, Acrylonitrile. Eleventh
52 Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology
53 Program.
54

- 1 O'Neil, M, Smith, A., Heckelman, P.E., Obenchain, J.R., Jr., Gallipeau, J. R., D'Arecca, M.A., (eds.). 2001.
2 Fluorine monoxide. The Merck Index. 13th edition. Merck & Co., Inc., Whitehouse Station, NJ., pp.
3 737-738.
4
- 5 Perbellini L, Ganzi A, Venturi G, Cerpelloni M., Brugnone F. 1998. Biological Monitoring of Acrylonitrile
6 Exposure. *G Ital Med Lav Ergon* 20: 10-14.
7
- 8 Perocco, P., Pane, G., Bolognesi, S., Zannotti, M. 1982. Increase in sister chromatid exchange and
9 unscheduled synthesis of deoxyribonucleic acid by acrylonitrile in human lymphocytes in vitro.
10 *Scand. J. Work Environ. Health*. 2-8: 290-293
11
- 12 Peter, H., Appel, K.E., Berg, R., Bolt, H.M. 1983. Irreversible binding of acrylonitrile to nucleic acids.
13 *Xenobiotica*, 13: 19-25.
14
- 15 Pilon, D., Roberts, A.E., Rickert, D.E. 1988. Effect of glutathione depletion on the uptake of acrylonitrile
16 vapors and on its irreversible association with tissue macromolecules. *Toxicol. Appl. Pharmacol.* 95:
17 265-278
18
- 19 Quast,, J.F., Schuetz, D.J., Balmer, M.F., Gushow, T.S., Park, C.N., McKenna, M.J. 1980. A two-year
20 toxicity and oncogenicity study with acrylonitrile following inhalation exposure of rats. Dow
21 Chemical Co. Toxicology Research Laboratory, Midland, MI. (for the Chemicals Manufacturing
22 Association, Washington, D.C.
23
24
- 25 Recio, L., Simpson, D., Cocharane, J., Liber, H., Skopek, T.R. 1989. Mutational specificity of
26 2-cyanoethylene oxide in human lymphoblastoid cells. *Environ. Mol. Mutagen.* 14 (Suppl. 15): 162
27
- 28 Recio L, Simpson D, Cochrane J, Liber H, Skopek TR. 1990. Molecular analysis of hprt mutants induced by
29 2-cyanoethylene oxide in human lymphoblastoid cells. *Mutat Res.* 242:195-208.
30
- 31 Rinehart, W. E., Hatch, T. (1964) Concentration-time product (CT) as an expression of dose in sublethal
32 exposures to phosgene. *Ind. Hyg. J.* 25: 545-553.
33
- 34 Rizzi, R., Chiesara, E., Cova, D., Mattioli, M., Lernia, R. 1984. Acrylonitrile: Mutagenicity in yeasts and
35 genotoxicity in HeLa cells. *Mutation Research* 130: 223.
36
- 37 Roberts, A.E., Kedderis, G.L., Turner, M.J., Rickert, D.E., Swenberg, J.A. 1991. Species comparison of
38 acrylonitrile epoxidation by microsomes from mice, rats and humans: Relationship to epoxide
39 concentrations in mouse and rat blood. *Carcinogenesis* 12: 401-404
40
- 41 Ruth, J.H. 1986. Odor thresholds and irritation levels of several chemical substances: a review. *Am. Ind. Hyg.*
42 *Assoc. J.* 47: A142-151.
43
- 44 Saillenfait, A.M., Bonnet, P., Guenier, J.P., De Ceaurriz, J. 1993a. Relative developmental toxicities of
45 inhaled aliphatic mononitriles in rats. *Fundam. Appl. Toxicol.* 20: 365-375.
46
- 47 Saillenfait, A.M., Payan, J.P., Langonne, I., Beydon, D., Grandclaude, M.C., Sabate, J.P., and de
48 Ceaurriz, J. 1993b. Modulation of acrylonitrile-induced embryotoxicity in vitro by glutathion
49 depletion. *Arch. Toxicol.* 67(3):164-172.
50
- 51 Sakurai, H., Kusumoto, M. 1972. Epidemiological study of health impairment among acrylonitrile workers.
52 *Journal of Science and labor.* 48: 273-282.
53

- 1 Sakurai, H., Onodera, M., Utsunomiya, T., Minakuchi, H., Iwai, H., Mutsumura, H. 1978. Health effects of
2 acrylonitrile in acrylic fibre factories. *Brit. J. Ind. Med.* 35, 219-225.
3
- 4 Sapphire Group. 2004. Toxicological Review for Acrylonitrile (CAS No. 107-13-1). Prepared for the AN
5 Group. The Sapphire Group, Inc., Dayton and Cleveland, OH. Final, October 2004.
6
- 7 SDU Uitgevers Nationale MAC List, 2000. (under the auspices of the Ministry of Social Affairs and
8 Employment), The Hague, The Netherlands.
9
- 10 Smyth, H.F., Jr. 1966. Military and space short-term inhalation standards. *AMA Arch.*
11 *Environ. Health.* 12: 488.
12
- 13 Sweeney LM, Gargas ML, Strother DE, Kedderis GL. (2003). Physiologically Based
14 Pharmacokinetic Model Parameter Estimation and Sensitivity and Variability Analyses for
15 Acrylonitrile Disposition in Humans. *Toxicological Sciences* 71: 27-40.
16
- 17 Sumner S. C., Fennell T. R., Moore T. A., Chanas B., Gonzalez F., Ghanayem B. I. 1999. Role of
18 Cytochrome P450 2E1 in the Metabolism of Acrylamide and Acrylonitrile in Mice. *Chem Res*
19 *Toxicol* 12: 1110-1116.
20
- 21 Tardif, R., Talbot, D., Grin, M., Brodeur, J. 1987. Urinary excretion of mercapturic acids and thiocyanate in
22 rats exposed to acrylonitrile: Influence of dose and route of administration. *Toxicology Letters* 39:
23 255-261.
24
- 25 ten Berge, W.F., Zwart, A., Appelman, L.M. 1986. Concentration-time mortality response relationship of
26 irritant and systemically acting vapours and gases. *J. Hazard Materials* 13: 301-309.
27
- 28 TERA (Toxicology Excellence for Risk Assessment). 1997. Acrylonitrile: inhalation cancer risk assessment.
29 Prepared for the Acrylonitrile Group. Toxicology Excellence for Risk Assessment, Cincinnati, OH.
30 Final Document (v.2). February 1997.
31
- 32 Thiess, A.M., Fleig, I. 1978. Analysis of chromosomes of workers exposed to acrylonitrile. *Arch. Toxicol.*
33 41: 149-152.
34
- 35 U.S. EPA (U.S. Environmental Protection Agency). 2005. Benchmark Dose Software.
36 Version 1.3.2 National Center for Environmental Assessment, Office of Research and Development.
37 [Online]. Available: <http://www.epa.gov/ncea/bmds.htm>
38
- 39 Vernon, P.A., Dulak, L. H., Deskin, R. (1990). Acute toxicologic evaluation of acrylonitrile. *J. Amer. Coll.*
40 *Toxicol.* 1: 114-115
41
- 42 Vodička, P., Gut, I., Frantik, E. 1990. Effects of inhaled acrylic acid derivatives in rats. *Toxicology* 65: 209-
43 221.
44
- 45 Vogel, R.A. and Kirkendall, W.M. 1984. Acrylonitrile (vinyl cyanide) poisoning: a case report. *Texas*
46 *Medicine* 80, 48-51.
47
- 48 Ward C.E., Starr T.B. 1993. Comparison of cancer risks projected from animal bioassays to epidemiologic
49 studies of acrylonitrile workers. *Regulat. Toxicol. Pharmacol.* 18: 214-232.
50
- 51 WHO IPCS (World Health Organization International Programme on Chemical Safety). 1983. Acrylonitrile.
52 *Environ Health Criteria*, No. 28.
53

- 1 WIL Research Laboratories. (2005). Acute inhalation toxicity study of acrylonitrile in albino rats. WIL
2 Research Laboratories, Ashland, OH. WIL-542001.
3
- 4 Willhite, C. C., Smith, R.P. 1981. The role of cyanide liberation in the acute toxicity of aliphatic nitriles.
5 Toxicol. Appl. Pharmacol. 59: 589-602.
6
- 7 Wilson, R.H., Hough, G.V., McCormick, W.E. 1948. Medical problems encountered in the manufacture of
8 American-made rubber. Ind. Med. 17: 199-207.
9
- 10 Wilson, R.H., McCormick, W.E. 1949. Acrylonitrile: its physiology and toxicology. Ind. Med. 17: 199-207.
11
- 12 Zotova, L.A. 1975. Working conditions in the production of acrylonitrile and their effect on workers. Gig. Tr.
13 Prof. Zabol. 8: 8-11.
14

1
2

APPENDIX A: Derivation of AEGL Values

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Derivation of AEGL-1 Values for Acrylonitrile

Key study: Jakubowski, M., Linhart, I., Pielas, G., Kopecky, J. 1987. 2-Cyanoethylmercapturic acid (CEMA) in the urine as a possible indicator of exposure to acrylonitrile. Brit. J. Industr. Med. 44: 834-840.

Critical effect: Occupational exposure reports indicated no effects at ≤ 10 ppm and ocular irritation and headaches at 12-15 ppm regardless of exposure duration (NAC/AEGL, pers. communication). A 3-fold reduction of the 15-ppm is equivalent to the no-effect concentration reported by Jakubowski et al. (1987) for male human volunteers exposed to 4.6 ppm AN for 8 hours.

Time scaling: none applied;

Uncertainty factors: Total uncertainty factor adjustment was 1:
Interspecies: none; human subjects
Intraspecies: 1; effects associated with very low-level AN exposure are not likely to vary among individuals; metabolism is not likely to play a significant role in very minor effects resulting from low-level exposure. An intraspecies UF of 3 applied to the lower limit of the occupational exposure range associated with ocular irritation and headache results in an exposure concentration equivalent to the no-effect concentration (4.6 ppm) reported by Jakubowski et al. (1987).

Modifying factor: None

Occupational exposure data indicated that for low exposures, exposure duration was irrelevant. Therefore, an AEGL-1 value of 4.6 ppm is recommended for all durations.

Derivation of AEGL-2 Values for Acrylonitrile

Key study: Dudley, H.C. and Neal, P.A. 1942. Toxicology of acrylonitrile (vinyl cyanide). I. Study of the acute toxicity. J. Ind. Hyg. Toxicol., 24 (2): 27-36.

Critical effect: Slight transient effects in rats exposed for 2 hours to 305 ppm AN. All effects were transient and resolved within 12 hours post exposure.
Support: Sakurai et al. (1978) noted that many of the symptoms (headache, fatigue, nausea, and insomnia) upon initial exposure observed for occupational exposure to AN were associated with exposures in excess of 5 ppm, and that the findings were not contradictory to those of Wilson et al. (1948) who reported that occupational exposure to 16-100 ppm for 20-45 minutes produced transient dull headaches, nasal and ocular irritation, discomfort in the chest, nervousness and irritability. Murray et al. (1978) provided evidence of teratogenicity in rats following multiple exposure to 80 ppm AN on gestation days 6-20 but effects in dams were limited to only food consumption and body weight decrease.

Time scaling: $C^n \times t = k$, where $n = 1.1$, ten Berge et al., 1986

Uncertainty factors: Total uncertainty factor adjustment was 10, additional uncertainty adjustment would result in AEGL-2 values that are inconsistent with the overall data and that would be similar to AEGL-1 values.

Interspecies: 3; PB-PK modeling has shown that predicted concentrations of AN and the metabolite CEO in blood and brain were similar in rats and humans exposed by inhalation.

Intraspecies: 3; the effects associated with acute AN exposure are not likely to vary greatly among individuals; metabolism is not likely to be instrumental in initial minor effects resulting from low-level exposure.

Modifying factor: None

Calculation: $(305 \text{ ppm})^{1.1} \times 2 \text{ hrs} = 1080 \text{ ppm}^{1.1} \text{ @hrs}$

10-minute AEGL-2

$$C^{1.1} \times 0.1667 \text{ hr} = 1080 \text{ ppm}^{1.1} \text{ @hrs}$$

$$C = 2917.4 \text{ ppm}$$

$$10\text{-min AEGL-2} = 2917.4 \text{ ppm}/10 = 291.7 \text{ ppm (rounded to 290 ppm)}$$

30-minute AEGL-2

$$C^{1.1} \times 0.5 \text{ hr} = 1080 \text{ ppm}^{1.1} \text{ @hrs}$$

$$C = 1074 \text{ ppm}$$

$$30\text{-min AEGL-2} = 1074 \text{ ppm}/10 = 107.4 \text{ ppm (rounded to 110 ppm)}$$

1	<u>1-hour AEGL-2</u>	
2		$C^{1.1} \times 1 \text{ hr} = 1080 \text{ ppm}^{1.1} \text{ @hrs}$
3		$C = 572.3 \text{ ppm}$
4		$1\text{-hr AEGL-2} = 572.3 \text{ ppm}/10 = 57.2 \text{ ppm (rounded to 57 ppm)}$
5		
6	<u>4-hour AEGL-2</u>	
7		$C^{1.1} \times 4 \text{ hrs} = 1080 \text{ ppm}^{1.1} \text{ @hrs}$
8		$C = 162.30 \text{ ppm}$
9		$4\text{-hr AEGL-2} = 162.3 \text{ ppm}/10 = 16.2 \text{ ppm (rounded to 16 ppm)}$
10		
11	<u>8-hour AEGL-2</u>	
12		$C^{1.1} \times 8 \text{ hrs} = 1080 \text{ ppm}^{1.1} \text{ @hrs}$
13		$C = 86.4 \text{ ppm}$
14		$8\text{-hr AEGL-2} = 86.4 \text{ ppm}/10 = 8.6 \text{ ppm}$

Derivation of AEGL-3 Values for Acrylonitrile

1	
2	
3	
4	Key studies:
5	Dudley, H.C. and Neal, P.A. 1942. Toxicology of acrylonitrile (vinyl cyanide). I. Study of the acute toxicity. J. Ind. Hyg. Toxicol., 24 (2): 27-36.
6	
7	Appel, K.E., Peter, H., Bolt, H.M. 1981a. Effect of potential antidotes on the acute toxicity of acrylonitrile. Int. Arch. Occup. Environ. Health 48: 157-163.
8	
9	
10	Critical effect:
11	Estimated lethality threshold (30-minute, 1-hr, 2-hr, 4-hr, and 8-hr BMCL ₀₅ values are 1784.0, 1024.4, 491.3, 179.5 and 185.8 ppm, respectively) for rats exposed to various concentrations of AN for 30 minutes, 1, 2, 4, or 8 hours. The 4-hr value was not used due to inconsistency with values of the other durations. The 4-hour AEGL was time-scaled using the 8-hour BMCL ₀₅ .
12	
13	
14	
15	
16	Time scaling:
17	$C^n \times t = k$, where $n = 1.1$, ten Berge et al. (1986); applied for derivation of 10-minute and 4-hour values only. The 30-minute, 1-hour and 8-hour AEGL-3 values were derived based upon their respective BMCL ₀₅ values.
18	
19	
20	Uncertainty factors:
21	Total uncertainty factor adjustment was 10.
22	<u>Interspecies</u> : 3; Although the dog appears to be the most sensitive species, the overall database for rats is more robust thereby justifying use of the rat data. PBPK model simulations (Kedderis and Fennell, 1996; Sweeney et al., 2003) indicated that predicted blood and brain concentrations of AN and the metabolite CEO (2-cyanoethylene oxide) were similar in rats and humans exposed to AN by inhalation. A factor of 3 is considered sufficient to account for possible toxicodynamic/metabolism differences
23	
24	<u>Intraspecies</u> : 3; For effects resulting from a single acute exposure, an intraspecies uncertainty factor of 3 would seem sufficient for accounting for variability in metabolism-mediated effects. Additional uncertainty factor application would result in incompatible AEGL-3 and AEGL-2 values.
25	
26	
27	
28	
29	
30	
31	
32	
33	Calculation:
34	For the 30-minute, 1-hr and 8-hr AEGL-3 values the 1-hr and 8-hr rat BMCL ₀₅ values were simply adjusted by the total uncertainty factor product of 10.
35	
36	The 10-minute values were derived by time-scaling from the 30-minute rat BMCL ₀₅ :
37	
38	$(1784 \text{ ppm})^{1.1} \times 0.5 \text{ hr} = 1885.8 \text{ ppm}^{1.1} \text{ Ahrs}$
39	
40	The 4-hr value was derived by scaling from the 8-hr rat BMCL ₀₅ (the 8-hr BMCL ₀₅ was considered more appropriate than the 2-hr value because it was derived from data for five dose groups rather than three):
41	
42	
43	$(185.8 \text{ ppm})^{1.1} \times 8 \text{ hrs} = 2506.3 \text{ ppm}^{1.1} \text{ Ahrs}$
44	
45	<u>10-minute AEGL-3</u>
46	$C^{1.1} \times 0.1667 \text{ hr} = 1885.8 \text{ ppm}^{1.1} \text{ @hrs}$
47	$C = 4842.4 \text{ ppm}$
48	$10\text{-min AEGL-3} = 4842.4 \text{ ppm}/10 = 484 \text{ ppm (rounded to 480 ppm)}$
49	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

30-minute AEGL-3

30-minute $BMCL_{05} = 1784$ ppm
 $1784 \text{ ppm}/10 = 178$ ppm (rounded to 180 ppm)

1-hour AEGL-3

1-hr $BMCL_{05} = 1024.42$ ppm
 $1024.42 \text{ ppm}/10 = 102$ ppm (round to 100 ppm)

4-hour AEGL-3

$C^{1.1} \times 4 \text{ hrs} = 2506.3 \text{ ppm}^{1.1} @\text{hrs}$
 $C = 348.9$ ppm
4-hr AEGL-3 = $348.9 \text{ ppm}/10 = 34.9$ ppm (round to 35 ppm)

8-hour AEGL-3

8-hr $BMCL_{05} = 185.8$ ppm
 $185.8 \text{ ppm}/10 = 18.6$ ppm (round to 19 ppm)

1
2

APPENDIX B: Time Scaling Calculations

1
2 The relationship between dose and time for any given chemical is a function of the physical
3 and chemical properties of the substance and the unique toxicological and pharmacological
4 properties of the individual substance. Historically, the relationship according to Haber (1924),
5 commonly called Haber's Law or Haber's Rule (i.e., $C \times t = k$, where C = exposure concentration, t =
6 exposure duration, and k = a constant) has been used to relate exposure concentration and duration to
7 effect (Rinehart and Hatch, 1964). This concept states that exposure concentration and exposure
8 duration may be reciprocally adjusted to maintain a cumulative exposure constant (k) and that this
9 cumulative exposure constant will always reflect a specific quantitative and qualitative response.
10 This inverse relationship of concentration and time may be valid when the toxic response to a
11 chemical is equally dependent upon the concentration and the exposure duration. However, an
12 assessment by ten Berge et al. (1986) of LC₅₀ data for certain chemicals revealed chemical-specific
13 relationships between exposure concentration and exposure duration that were often exponential.
14 This relationship can be expressed by the equation $C^n \times t = k$, where n represents a chemical
15 specific, and even a toxic endpoint specific, exponent. The relationship described by this equation is
16 basically the form of a linear regression analysis of the log-log transformation of a plot of C vs t . ten
17 Berge et al. (1986) examined the airborne concentration (C) and short-term exposure duration (t)
18 relationship relative to death for approximately 20 chemicals and found that the empirically derived
19 value of n ranged from 0.8 to 3.5 among this group of chemicals. Hence, the value of the exponent
20 (n) in the equation $C^n \times t = k$ quantitatively defines the relationship between exposure concentration
21 and exposure duration for a given chemical and for a specific health effect endpoint. Haber's Rule is
22 the special case where $n = 1$. As the value of n increases, the plot of concentration vs time yields a
23 progressive decrease in the slope of the curve.

24
25 For acrylonitrile, analysis of available data by ten Berge et al. (1986) showed that the
26 relationship between exposure concentration and exposure duration was near linear, where $n = 1.1$
27 for the relationship $C^n \times t = k$.

28

1
2

APPENDIX C: AEGL DERIVATION SUMMARY TABLES

1
2
3
4
5

**ACUTE EXPOSURE GUIDELINE LEVELS FOR
ACRYLONITRILE
DERIVATION SUMMARY**

AEGL-1 VALUES FOR ACRYLONITRILE				
10 min	30 min	1 h	4 h	8 h
4.6 ppm	4.6 ppm	4.6 ppm	4.6 ppm	4.6 ppm
Reference: Jakubowski, M., Linhart, I., Pielas, G., Kopecky, J. 1987. 2-Cyanoethylmercapturic acid (CEMA) in the urine as a possible indicator of exposure to acrylonitrile. Brit. J. Industr. Med. 44: 834-840.				
Test Species/Strain/Number: six informed volunteer male humans subjects				
Exposure Route/Concentrations/Durations: inhalation/ 2.3 or 4.6 ppm AN for 8 hours				
Effects: no effects in any of the subjects at either exposure level				
Endpoint/Concentration/Rationale: 4.6 ppm AN for 8 hours is considered a NOAEL				
Uncertainty Factors/Rationale: Total uncertainty factor adjustment was 3: <u>Interspecies</u> : None; human subjects <u>Intraspecies</u> : 1; Effects associated with very low-level acute AN exposure are not likely to vary among individuals; metabolism will not be instrumental in initial, minor effects				
Based upon occupational exposure data showing no effects at concentrations of 10 ppm AN, further reduction of the AEGL-1 values is not warranted.				
Modifying Factor: None applied				
Animal to Human Dosimetric Adjustment: no adjustments				
Time Scaling: None applied; occupational data suggest that minor irritation effect occur immediately and are independent of exposure duration				
Data Adequacy: AEGL-1 values for acrylonitrile are developed based upon results from a controlled experiment with human volunteer subjects with incorporation of occupational exposure data. The data effectively define a no-observed-adverse-effect level for acrylonitrile and for an AEGL-specific exposure duration.				

1

AEGL-2 VALUES FOR ACRYLONITRILE				
10 minutes	30 min	1 h	4 h	8 h
290 ppm	100 ppm	57 ppm	16 ppm	8.6 ppm
Reference: Dudley, H.C. and Neal, P.A. 1942. Toxicology of acrylonitrile (vinyl cyanide). I. Study of the acute toxicity. J. Ind. Hyg. Toxicol., 24 (2): 27-36.				
Test Species/Strain/Sex/Number: Osborne-Mendel rat; 16/group				
Exposure Route/Concentrations/Durations: inhalation; 305 ppm for 2 hours				
Effects: slight initial alteration in respiratory rate, slight, transient nasal and ocular irritation; effects transient and resolved by 12 hours post exposure				
Endpoint/Concentration/Rationale: slight transient effects following 2-hour exposure to 305 ppm.				
Uncertainty Factors/Rationale: Total uncertainty factor adjustment was 10 <u>Interspecies</u> : 3; All species tested exhibited similar array of effects <u>Intraspecies</u> : 3; The effects associated with acute AN exposure are not likely to vary greatly among individuals; metabolism is not likely to be instrumental in minor effects resulting from low-level exposure.				
Modifying Factor: none				
Animal to Human Dosimetric Adjustment: Not applicable				
Time Scaling: $C^n \times t = k$, where $n = 1.1$ as reported by ten Berge et al. 1986				
Data Adequacy: The AEGL-2 value are based upon effects that are indicative of AN exposure but not yet demonstrating more severe toxicity (e.g., convulsions, extreme respiratory alterations) or irreversible effects. The test species is a nonhuman primate considered to be more appropriate than rodents or other test species.				

2

AEGL-3 VALUES FOR ACRYLONITRILE				
10 min	30 min	1 h	4 h	8 h
480 ppm	180 ppm	100 ppm	35 ppm	19 ppm
Reference: Dudley, H.C. and Neal, P.A. 1942. Toxicology of acrylonitrile (vinyl cyanide). I. Study of the acute toxicity. J. Ind. Hyg. Toxicol., 24 (2): 27-36.				
Appel, K.E., Peter, H., Bolt, H.M. 1981. Effect of potential antidotes on the acute toxicity of acrylonitrile. Int. Arch. Occup. Environ. Health 48: 157-163.				
Test Species/Strain/Sex/Number: 16 Osborne-Mendel rats (gender not specified) per exposure concentration (Dudley and Neal, 1942); 3-6 male Wistar rats (Appel et al., 1981)				
Effects: Lethal response frequency (see Tables 2 & 4, Section 3.1.2 for details) for details.				
<u>Exposure duration (h)</u>		<u>Exposure concentration (ppm)</u>		<u>Mortality</u>
0.5 (Appel et al., 1981)		1600		0/3
		2600		1/3
		3000		6/6
1 (Dudley and Neal, 1942)		665		0/16
		1270		0/16
		1490		4/16
		2445		13/16
2 (Dudley and Neal, 1942)		305		0/16
		595		1/16
		1260		16/16
4 (Dudley and Neal, 1942)		130		0/16
		315		2/16
		635		16/16
8 (Dudley and Neal, 1942)		90		0/16
		135		0/16
		210		1/16
		270		7/16
		320		15/16
Endpoint/Concentration/Rationale: Estimated lethality threshold (30-minute, 1-hr, 2-hr,4-hr, and 8-hr BMCL ₀₅ values are 1784.0, 1024.4, 491.3, 179.5 and 185.8 ppm, respectively) for rats exposed to various concentrations of AN for 30 minutes, 1, 2, 4, or 8 hours. The 4-hr value was not used due to inconsistency with values of the other durations.				
Uncertainty Factors/Rationale: Total uncertainty factor adjustment was 10				
<u>Interspecies:</u> 3; Although the dog appears to be the most sensitive species, the overall database for rats is more robust thereby justifying use of the rat data. PBPK model simulations (Kedderis and Fennell, 1996; Sweeney et al., 2003) indicated that predicted blood and brain concentrations of AN and the metabolite CEO (2-cyanoethylene oxide) were similar in rats and humans exposed to AN by inhalation. A factor of 3 is considered sufficient to account for possible toxicodynamic/metabolism differences.				
<u>Intraspecies:</u> For effects resulting from a single acute exposure, an intraspecies uncertainty factor of 3 would seem sufficient for accounting for variability in metabolism-mediated effects. Additional uncertainty factor application would result in incompatible AEGL-3 and AEGL-2 values.				
Modifying Factor: None applied				
Animal to Human Dosimetric Adjustment: Not applicable				
Time Scaling: For the 30-minute, 1-hr, and 8-hr AEGL-3 values, the corresponding rat BMCL ₀₅ values were simply adjusted by the total uncertainty factor product of 10.				
The 10-minute value was derived by time-scaling from the 3-min. rat BMCL ₀₅ : (1578 ppm) ^{1.1} x 0.5 hr = 1647.7 ppm ^{1.1} Ahrs				
The 4-hr values was derived by scaling from the 8-hr rat BMCL ₀₅ (the 8- hr BMCL ₀₅ was considered more appropriate that the 2-hr value because it was derived from data for five dose groups rather than three): (185.8 ppm) ^{1.1} x 8 hrs = 2506.3 ppm ^{1.1} Ahrs				
Data Adequacy: Although definitive exposure response data for lethality in humans are not available, data are available from acute and subchronic bioassays in multiple species. These data are sufficient for development of scientifically justified AEGL values.				

1
2

APPENDIX D: BMC ANALYSIS FOR ACRYLONITRILE

1
2 **BMCL₀₁ 30-minute exposure of rats to acrylonitrile (Appel et al., 1981)**

3
4
5 =====
6 Probit Model. (Version: 2.8; Date: 02/20/2007)
7 Input Data File: C:\BMDS\APPEL_30-MIN.(d)
8 Gnuplot Plotting File: C:\BMDS\APPEL_30-MIN.plt
9 Fri Jul 13 13:22:35 2007
10 =====

11 **BMDS MODEL RUN**

12 ~~~~~
13
14 The form of the probability function is:
15 $P[\text{response}] = \text{Background} + (1 - \text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose}))$,
16 where CumNorm(.) is the cumulative normal distribution function

17
18 Dependent variable = COLUMN3
19 Independent variable = COLUMN1
20 Slope parameter is not restricted

21
22 Total number of observations = 3
23 Total number of records with missing values = 0
24 Maximum number of iterations = 250
25 Relative Function Convergence has been set to: 1e-008
26 Parameter Convergence has been set to: 1e-008

27
28 User has chosen the log transformed model
29 Default Initial (and Specified) Parameter Values
30 background = 0
31 intercept = -30.2755
32 slope = 3.91797

33
34 **Asymptotic Correlation Matrix of Parameter Estimates**

35
36 (*** The model parameter(s) -background -slope
37 have been estimated at a boundary point, or have been specified by the user,
38 and do not appear in the correlation matrix)

39
40
41 intercept intercept
42 1

43 **Parameter Estimates**

44 **95.0% Wald Confidence Interval**

Variable	Estimate	Std. Err.	Lower Conf. Limit	Upper Conf. Limit
background	0	NA		
intercept	-141.863	0.665192	-143.167	-140.559
slope	18	NA		

45
46
47
48

1
 2 NA - Indicates that this parameter has hit a bound
 3 implied by some inequality constraint and thus
 4 has no standard error.

5
 6 Analysis of Deviance Table

7 Model	Log(likelihood)	# Param's	Deviance	Test d.f.	P-value
8 Full model	-1.90954	3			
9 Fitted model	-1.99323	1	0.167371	2	0.9197
10 Reduced model	-8.15032	1	12.4816	2	0.001948
11 AIC:	5.98646				

12
 13
 14
 15 Goodness of Fit


16 Dose	Est._Prob.	Expected	Observed	Scaled Size	Residual
17 1600.0000	0.0000	0.000	0	3	-0.000
18 2600.0000	0.3729	1.119	1	3	-0.142
19 3000.0000	0.9878	5.927	6	6	0.272

20
 21
 22
 23 Chi^2 = 0.09 d.f. = 2 P-value = 0.9541

24
 25 Benchmark Dose Computation

26 Specified effect = 0.05
 27 Risk Type = Extra risk
 28 Confidence level = 0.95
 29 BMC = 2416.07
 30 **BMCL = 1784.1**

31
 32
 33



1

10:14 07/11 2007

1
2 **BMCL₀₅ 1-hr exposure of rats (Dudley and Neal, 1942)**
3
4

```
=====
5       Probit Model $Revision: 2.1 $ $Date: 2000/02/26 03:38:53 $
6       Input Data File: C:\BMDS\UNSAVED1.(d)
7       Gnuplot Plotting File: C:\BMDS\UNSAVED1.plt
8                                     Thu Mar 01 08:34:09 2007
9     =====
```

10
11 **BMDS MODEL RUN**
12 ~~~~~

13 The form of the probability function is:

14 $P[\text{response}] = \text{Background} + (1-\text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose}))$,
15 where CumNorm(.) is the cumulative normal distribution function

16
17 Dependent variable = COLUMN3
18 Independent variable = COLUMN1
19 Slope parameter is not restricted

20
21 Total number of observations = 4
22 Total number of records with missing values = 0
23 Maximum number of iterations = 250
24 Relative Function Convergence has been set to: 1e-008
25 Parameter Convergence has been set to: 1e-008

26
27 User has chosen the log transformed model

28
29 **Default Initial (and Specified) Parameter Values**

30 background = 0
31 intercept = -16.2084
32 slope = 2.13067

33
34 **Asymptotic Correlation Matrix of Parameter Estimates**

35 (*** The model parameter(s) -background have been estimated at a boundary point, or
36 have been specified by the user, and do not appear in the correlation matrix)

37
38

	intercept	slope
intercept	1	-1
slope	-1	1

39
40
41
42 **Parameter Estimates**

43

Variable	Estimate	Std. Err.
background	0	NA
intercept	-29.6647	6.43448
slope	3.92636	0.860001

44
45
46
47
48
49 NA - Indicates that this parameter has hit a bound implied by some inequality constraint and

thus has no standard error.

Analysis of Deviance Table

Model	Log(likelihood)	Deviance	Test DF	P-value
Full model	-16.7186			
Fitted model	-18.0178	2.5984	2	0.2728
Reduced model	-37.047	40.6567	3	<.0001
AIC:	40.0356			


Goodness of Fit

Dose	Est._Prob.	Expected	Scaled Observed	Size	Residual
665.0000	0.0000	0.000	0	16	-0.01652
1270.0000	0.0544	0.870	0	16	-0.9591
1490.0000	0.1644	2.630	4	16	0.9241
2445.0000	0.8335	13.336	13	16	-0.2251
Chi-square =	1.82	DF = 2	P-value = 0.4015		

Benchmark Dose Computation

Specified effect = 0.05
 Risk Type = Extra risk
 Confidence level = 0.95
 BMC = 1256.83
BMCL = 1024.42

Probit Model with 0.95 Confidence Level



BMCL₀₅ 2-hr exposure of rats (Dudley and Neal, 1942)

=====
 Probit Model \$Revision: 2.1 \$ \$Date: 2000/02/26 03:38:53 \$
 Input Data File: C:\BMDS\UNSAVED1.d
 Gnuplot Plotting File: C:\BMDS\UNSAVED1.plt
 Thu Mar 01 08:39:20 2007
 =====

BMDS MODEL RUN

The form of the probability function is:

$$P[\text{response}] = \text{Background} + (1 - \text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose})),$$

where CumNorm(.) is the cumulative normal distribution function

Dependent variable = COLUMN3
 Independent variable = COLUMN1
 Slope parameter is not restricted

Total number of observations = 3
 Total number of records with missing values = 0
 Maximum number of iterations = 250
 Relative Function Convergence has been set to: 1e-008
 Parameter Convergence has been set to: 1e-008

User has chosen the log transformed model
 Default Initial (and Specified) Parameter Values
 background = 0
 intercept = -17.8516
 slope = 2.70268

Asymptotic Correlation Matrix of Parameter Estimates

(*** The model parameter(s) -background have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix)

	intercept	slope
intercept	1	-1
slope	-1	1

Parameter Estimates

Variable	Estimate	Std. Err.
background	0	NA
intercept	-64.9721	4558.92
slope	9.92993	713.606

NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus has no standard error.

Analysis of Deviance Table

Model	Log(likelihood)	Deviance	Test DF	P-value
Full model	-3.74067			
Fitted model	-3.74067	5.37593e-008	1	0.9998
Reduced model	-31.199	54.9175	2	<.0001
AIC:	11.4813			

Goodness of Fit

Dose	Est._Prob.	Expected	Scaled Observed	Size	Residual
305.0000	0.0000	0.000	0	16	-4.972e-008
595.0000	0.0625	1.000	1	16	-3.32e-005
1260.0000	1.0000	16.000	16	16	0.0001623

Chi-square = 0.00 DF = 1 P-value = 0.9999

Benchmark Dose Computation

Specified effect = 0.05


Risk Type = Extra risk

Confidence level = 0.95

BMC = 588.401

BMCL = 491.304

Probit Model with 0.95 Confidence Level



10:21 07/11 2007

1 **BMCL₀₅ 4-hr exposure of rats (Dudley and Neal, 1942)**

2
3
4 =====
5 Probit Model \$Revision: 2.1 \$ \$Date: 2000/02/26 03:38:53 \$
6 Input Data File: C:\BMDS\UNSAVED1.d
7 Gnuplot Plotting File: C:\BMDS\UNSAVED1.plt
8 Thu Mar 01 08:43:13 2007
9 =====

10 **BMDS MODEL RUN**

11 ~~~~~
12 The form of the probability function is:

13 $P[\text{response}] = \text{Background} + (1 - \text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose}))$, where CumNorm(.) is the cumulative
14 normal distribution function
15

16
17 Dependent variable = COLUMN3
18 Independent variable = COLUMN1
19 Slope parameter is not restricted

20
21 Total number of observations = 3
22 Total number of records with missing values = 0
23 Maximum number of iterations = 250
24 Relative Function Convergence has been set to: 1e-008
25 Parameter Convergence has been set to: 1e-008

26
27 User has chosen the log transformed model

28
29 **Default Initial (and Specified) Parameter Values**

30 background = 0
31 intercept = -13.5273
32 slope = 2.34824
33

34 **Asymptotic Correlation Matrix of Parameter Estimates**

35 (*** The model parameter(s) -background have been estimated at a boundary point, or
36 have been specified by the user, and do not appear in the correlation matrix)

37
38

	intercept	slope
intercept	1	-1
slope	-1	1

39
40
41

42 **Parameter Estimates**

43

Variable	Estimate	Std. Err.
background	0	NA
intercept	-50.8405	3148.13
slope	8.75291	547.256

44
45
46
47

48 NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus
49 has no standard error.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Analysis of Deviance Table

Model	Log(likelihood)	Deviance	Test DF	P-value
Full model	-9.93738			
Fitted model	-9.93738	2.60525e-007	1	0.9996
Reduced model	-32.8951	45.9154	2	<.0001
AIC:	23.8748			


Goodness of Fit

Dose	Est_Prob.	Expected	Observed	Scaled Size	Residual
130.0000	0.0000	0.000	0	16	-3.783e-008
315.0000	0.3125	5.000	5	16	-3.304e-006
635.0000	1.0000	16.000	16	16	0.0003609
Chi-square =	0.00	DF = 1	P-value = 0.9997		

Benchmark Dose Computation

Specified effect = 0.05
 Risk Type = Extra risk
 Confidence level = 0.95
 BMC = 276.026
BMCL = 179.532

Probit Model with 0.95 Confidence Level



1 **BMCL₀₅ 8-hr exposure of rats (Dudley and Neal, 1942)**

2
3
4 =====
5 Probit Model \$Revision: 2.1 \$ \$Date: 2000/02/26 03:38:53 \$
6 Input Data File: C:\BMDS\UNSAVED1.d
7 Gnuplot Plotting File: C:\BMDS\UNSAVED1.plt
8 Thu Mar 01 08:46:12 2007
9 =====

10 **BMDS MODEL RUN**

11 ~~~~~
12 The form of the probability function is:

13 $P[\text{response}] = \text{Background} + (1 - \text{Background}) * \text{CumNorm}(\text{Intercept} + \text{Slope} * \text{Log}(\text{Dose}))$,
14 where CumNorm(.) is the cumulative normal distribution function

15
16 Dependent variable = COLUMN3
17 Independent variable = COLUMN1
18 Slope parameter is not restricted

19
20 Total number of observations = 5
21 Total number of records with missing values = 0
22 Maximum number of iterations = 250
23 Relative Function Convergence has been set to: 1e-008
24 Parameter Convergence has been set to: 1e-008

25
26 User has chosen the log transformed model
27 Default Initial (and Specified) Parameter Values
28 background = 0
29 intercept = -13.
30 slope = 2.37276

31
32 Asymptotic Correlation Matrix of Parameter Estimates
33 (*** The model parameter(s) -background have been estimated at a boundary point, or have
34 been specified by the user, and do not appear in the correlation matrix)

35
36

	intercept	slope
intercept	1	-1
slope	-1	1

37
38
39
40
41

Parameter Estimates		
Variable	Estimate	Std. Err.
background	0	NA
intercept	-40.1969	9.34116
slope	7.18845	1.66722

42
43
44
45
46
47 NA - Indicates that this parameter has hit a bound implied by some inequality constraint and thus
48 has no standard error.
49

1 Analysis of Deviance Table

2 Model	Log(likelihood)	Deviance	Test DF	P-value
3 Full model	-18.4464			
4 Fitted model	-18.9141	0.935409	3	0.8169
5 Reduced model	-47.991	59.091	4	<.0001
6 AIC:	41.8281			

7
8 Goodness of Fit


9
10 Scaled

11 Dose	Est._Prob.	Expected	Observed	Size	Residual
12 -----					
13 90.0000	0.0000	0.000	0	16	-1.822e-007
14 135.0000	0.0000	0.000	0	16	-0.002528
15 210.0000	0.0392	0.628	1	16	0.479
16 270.0000	0.5188	8.300	7	16	-0.6506
17 320.0000	0.8977	14.363	15	16	0.5257
18 Chi-square =	0.93	DF = 3	P-value = 0.8184		

19
20 Benchmark Dose Computation

21 Specified effect = 0.05
 22 Risk Type = Extra risk
 23 Confidence level = 0.95
 24 BMC = 213.376
 25 **BMCL = 185.797**

26
Probit Model with 0.95 Confidence Level



10:06 07/11 2007

1
2

APPENDIX E: Litchfield and Wilcoxon LC₅₀ Calculation

Dudley and Neal (1942): rat lethality 1-hr exposure to AN

Dose	Mortality	Observed%	Expected%	Observed-Expected	Chi-Square
665.000	0/ 16	0(0.30)	0.28	0.02	0.0000
1270.000	0/ 16	0(3.80)	9.95	-6.15	0.0422
1490.000	4/ 16	25.00	21.53	3.47	0.0071
2445.000	13/ 16	81.25	82.13	-0.88	0.0005

Values in parentheses are corrected for 0 or 100 percent Total = 0.0499

LC₅₀ = 1870.153(1621.558 - 2156.859)*

Slope = 1.34(1.22 - 1.47)*


* These values are 95 percent confidence limits

Total animals = 64 Total doses = 4 Animals/dose = 16.00

Chi-square = total chi-square X animals/dose = 0.7986

Table value for Chi-square with 2 Degrees of Freedom = 5.9900

LC₈₄ = 2502.530 LC₁₆ = 1397.574 FED = 1.15 FS = 1.10 A = 1.07



ACRYLONITRILE

		Expected Lethal Dose Values
1		
2		
3	LC _{0.1}	555.726
4		
5	LC _{1.0}	834.159
6		
7	LC _{5.0}	1114.816
8		
9	LC ₁₀	1271.215
10		
11	LC ₂₅	1541.871
12		
13	LC ₅₀	1870.153
14		
15	LC ₇₅	2268.330
16		
17	LC ₉₀	2751.283
18		
19	LC ₉₉	4192.812
20		
21		
22		
23		
24		
25		


1 **APPENDIX F: CARCINOGENICITY ASSESSMENT FOR ACRYLONITRILE**
2

1
2 Various inhalation unit risk values have been developed for acrylonitrile (see Section 2.5).
3 IARC (1999) downgraded AN from category 2a to category 2b noting that data relative to human
4 carcinogenicity are inadequate and that no causal association exists. Current data are sufficient for
5 considering AN to be carcinogenic in animals (NTP, 2002). That AN would induce a carcinogenic
6 response in humans following a single, once-in-a-lifetime acute exposure is remote. |
7

1
2

APPENDIX G: CATEGORY PLOT FOR ACRYLONITRILE

1
2
3
4
5



6
7
8
9